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ONE-HALF PHEN IN THE MORNING/ ONE FEN
BEFORE DINNER:
A PROPOSAL FOR FDA REGULATION OF OFF-
LABEL USES OF DRUGS*
Jaime A. Wilsker*
When a nearly untested drug combination enters the
obesity market in a country where people are willing to try
almost anything that promises to help them shed pounds,
you have a potential disaster on your hands.'
* The term "off-label" refers to the practice of prescribing drugs for uses that
have not been approved by the Federal Drug Administration ("FDA"). Marlene
Cimons, Public Policy: FDA 's Approval Process Faces Challenge in New Senate
Bill Finding the Proper Balance Between Protecting and Overburdening
Americans is at the Heart of Renewed Debate Over the Agency's Mission, L.A.
TIMEs, July 22, 1997, at A5. Fen-phen, for example, is a two-drug combination
that was not FDA approved. Id. (noting that some 40-60% of all prescriptions
are off-label uses). See also Fen/Phen: Unapproved Drug-2: Bill Seen Helping
Cancer Doctors, Dow JONES NEWS SERVICE, July 21, 1997, at 18:15:00;
Kathleen Kerr, Drug Makers Seek Return of Redux, N.Y. NEWSDAY, Nov. 12,
1997, at A24 (noting another example of off-label dispensing, namely, the drug
Redux (dexfenfluramine)). Although available in Europe for a long time, the
FDA approved Redux only last year "after what some researchers believe was a
shallow review of the adverse effects." Terence Monmaney, Diet Drugs Said To
Kill Off Some Brain Cells, AUSTIN AMER.-STATESMAN, Aug. 27, 1997, at Al.
Similar to fen-phen, Redux is another controversial diet pill that has been
recently removed from pharmacies as a result of widespread concern with heart
valve problems. Kerr, supra, at A24. Manufacturers are seeking to put Redux
back on the market for treatment of psychiatric disorders. Kerr, supra, at A24.
** Brooklyn Law School Class of 1999; B.A., Vassar College, 1996. The
author wishes to extend a heartfelt thank you to her parents for their invaluable
advice, her sister for her continual support and to Howard Heath Tygar for his
love and encouragement.
Gina Kolata, Millions Flock to Diet Drugs, But Risks Are Emerging, PITTS-
BURGH POST-GAZETTE, July 20, 1997, at A3. Not since the 1970's craze with
amphetamines have diet pills gained such popularity. Id. Yet, this craze begs the
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INTRODUCTION
Desperation leads people to the "miracle" bottle for a quick fix
weight loss drug like fen-phen.2
It's not just being able to wear shorts in public. It's being
able to squat down to the bottom drawers of the file
cabinet. It's being able to bend her leg enough to work the
parking brake in her blue Chevy pick-up. It's being able to
fit through the turnstile at Blockbuster.'
For many, "[t]he promise of a thinner, happier life was contained
in two little syllables-Fen-phen." '4 However, the advent of the
so-called "fen-phen cocktail" makes it ever more apparent that
question, "[w]hat are people willing to risk to be slim?" Id.
2 See Thomas N. Tiedt, et al., Pharmacotherapy in The Management Of
Obesity, 277 JAMA 1201, 1201 (1997). "Diet pills are at best only signals to
stick to required diet and exercise." Id.
a Roger Bull, Fen-phen Fear: Is Weight Loss Worth the Health Risk?, FLA.
TIMES-UNION, Aug. 26, 1997, at D 1. Fen-phen has become a last resort for many
obese people. Id. In the past Kim Fraley had tried Weight Watchers, Nutrisystem,
Jenny Craig and the Mayo Diet and lost a few pounds which she eventually
gained back. Id. The battle over weight gain began for Fraley in high school
when she became unable to participate in sports due to a knee injury. Id. Two
years later she became pregnant and gained an additional sixty-five pounds. Id.
Earlier this year, at age twenty-five, Fraley weighed over 324 pounds. Id. She
has currently dropped to 250 pounds by taking fen-phen. Id. Ann Diamond,
another fen-phen user, was satisfied with the results (losing nine pounds in seven
weeks), but has quit taking the diet drug due to reports linking fen-phen to
pulmonary hypertension. Id.
" Jennifer Brett, Dieters Hear Fen-phen Warnings, ST. PETERSBURG TIMES,
Aug. 3, 1997, at 1. Dana Reuter tried almost every diet, none of which helped
her lose weight and keep it off. Id. "Then something that seemed almost magical
came along: pills she could take that would stamp out her appetite and boost her
energy. The pounds would melt off. Slim jeans were in her future." Id. At age
47, after taking half a pill at a time for close to three months, Reuter claims that
she had no appetite which resulted in a loss of 30 pounds. Id. Like Ann
Diamond, Reuter quit taking fen-phen because of concern over the development
of deformed heart valves in others who ingested the drug. Id.
796
FEN-PHEN
"succumbing to the allure of diet pills as a quick fix for excess
weight may be courting disaster."5
In the age of a "wonder drug" for just about everything, the
battle between the health and safety needs of society and the rights
of the drug industry to sell its products with as little governmental
intrusion as possible becomes far more serious when a third
element is added-off-label prescriptions. Off-label prescriptions
allow for the dispensing of drugs for uses that have not been
approved by the Federal Drug Administration ("FDA").6 Fen-phen,
for example, is a combination of two appetite suppressants, each
individually approved by the FDA for short-term use,7 but the
concomitant use of both drugs is neither approved nor recom-
mended by either the FDA or the manufacturers.8 Still, it is legal
5 Robert Langreth, Medicine: Eminent Journal Urges Moratorium on Diet
Drug Use, WALL ST. J., Aug. 28, 1997, at BI. The FDA has begun gathering
information on the rate of occurrence of adverse side effects with fen-phen in
order to decide what steps, if any, should be taken. Id. For example, more
warnings, changes in recommended dosages or length of time the drugs should
be prescribed for are under consideration. Id. Meanwhile, a few patients are
ceasing their use of the drug in light of possible heart valve side effects. Id.
6 Cimons, supra note *, at A5. See also Robert Langreth & Bruce Ingersoll,
Pharmaceuticals: Diet-Drug Mix May Damage Heart Valves, WALL. ST. J., July
9, 1997, at B 1 (noting that absent FDA approval of the combined use of
fenfluramine and phentermine, doctors have been prescribing their concomitant
use in recent years).
' Heart Disease Link to Diet Drugs Prompts FDA Action, MARKETLETTER,
July 21, 1997, available in 1997 WL 11870685, at ISSN 0951-3175. Both drugs
are approved as "monotherapies for severe obesity." Id. Fenfluramine Hydro-
chloride is implicated in the management of exogenous obesity as a short term
(a few weeks) adjunct in a weight reduction regimen based on caloric restriction.
See PHYSICIANS' DESK REFERENCE: PRODUCT INFORMATION, ISBN: 1-56363-
151-2, at 1288-89 (1996) [hereinafter PDR]. Phentermine has the identical
indications with the additional language, "the limited usefulness of agents of this
class should be measured against possible risk factors inherent in their use."
PDR, supra, at 2464-66.
S Murray M. Lumpkin, M.D., Public Health Advisory: Reports of Valvular
Heart Disease in Patients Receiving Concomitant Fenfluramine andPhentermine,
(last modified Aug. 28, 1997)<http://www.fda.gov/cder/phenfen.html>. This
public health advisory provides:
We strongly encourage all health care professionals to report any
cardiac valvular disease or other serious toxicities associated with the
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and quite common for doctors to prescribe a drug to be used for an
indication which was never FDA approved.9 Physicians who
prescribe fen-phen and other off-label prescriptions are, in effect,
creating a new drug that has not been proved generally safe and
effective for human consumption. ° As concerns over side-effects
grow and as new reports begin to link these drugs to primary
pulmonary hypertension, rare heart valve disorders, and even brain
damage," will no one stop to ask: who will regulate doctors when
use of fenfluramine, dexfenfluramine, or phentermine to the FDA's
MEDWATCH program at 1-800-FDA-1088/fax 1-800-FDA-1078, or
to the respective pharmaceutical manufacturers. Of particular interest
in such cases would be the dosage and duration of therapy with the
drug product(s), whether there were any other medications being taken
by the patient on a chronic basis, whether there was any history of pre-
existent cardiac disease, the results of the patient's cardiac examination,
and the degree of obesity at the time of the initial therapy with the
drug(s).
Id. Dr. Lumpkin is the Deputy Center Director for Drug Evaluation and Research
for the FDA. Id. Fenfluramine is sold by American Home Products Corporation
as Pondimin. See Langreth, supra note 5, at B 1. Phentermine is sold by Smith
Kline Beecham PLC and several smaller manufacturers. See Langreth, supra note
5, at B 1. American Home Products asserted that the reports linking heart valve
damage to fen-phen are "inconclusive." Langreth, supra note 5, at B 1.
9 Kathleen Kerr, New Heart Cases Spur Fen-phen Label Move, N.Y.
NEWSDAY, Aug. 28, 1997, at A52. "The combination was tested by millions of
Americans who decided it was the easy answer to their weight-loss woes based
on the sales pitches of diet centers, doctors, Internet ads, and fliers on lamp-
posts." Nancy Shute, Pills Don't Come With A Seal Of Approval, U.S. NEWS &
WORLD REP., Sept. 29, 1997, at 7475.
'0 Robert Kushner, M.D., The Treatment of Obesity: A Call for Prudence
and Professionalism, 157 ARCHIVES OF INTERNAL MEDICINE 602, 603 (1997).
The physician's greatest asset is the ability to seize on the drug frenzy to lose
weight that is popularized in women's magazines, on television and almost
inescapable in modem-day society. Id. The physicians appear as superheros,
ready to conquer the evil of obesity, armed with the perfect panacea. Id. Not too
far behind, the commercial weight loss programs are starting to incorporate
pharmacotherapy into their diet regimens. Id.
" Robert Langreth, Pressure in US. Builds to Restrict Diet Drugs, WALL
ST. J. (Europe), Aug. 28, 1997, at 3. The most recent side-effect report tells of
a 29-year-old woman who died of pulmonary hypertension after taking fen-phen
for only 23 days. Id. The autopsy revealed lung damage similar to that caused
by Aminorex, which was banned in the late 1960's in Europe after it was
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they are free to prescribe approved drugs for any and all uses they
desire?
This Note examines the best way to protect society against the
desire and, with the advent of fen-phen, ability to self-medicate in
an effort to attain the American ideal that beauty and thinness are
one in the same. In particular, this Note argues that off-label uses
of such prescription drugs must fall under FDA supervision. Part
I will examine the development of the FDNs supervisory role in
the regulation of prescription drugs. Part II will address the
manufacturers' liability for prescription drugs under the Restate-
ment (Second) of Torts, section 402A, comment k and current case
law. Part III will discuss Fenfluramine and Phentermine. Part IV
provides a proposal which would grant the FDA authority to
oversee off-label dispensing of drugs. This Note concludes that the
FDA must take an active role in the regulation of off-label
dispensing of drugs to ensure greater consumer safety.
I. THE DEVELOPMENT OF THE FDA'S SUPERVISORY ROLE
Drugs and medical devices are the most heavily regulated
consumer products in our society. 2 As set forth by statute, 13 the
FDA is the primary agency concerned with the regulation of
pharmaceuticals. 14 Congress delegated to the FDA the power to
protect individuals by regulating which drugs will be deemed safe
and effective.15 Since the "drug" category is broad, generalizations
implicated in many deaths. Id.
12 Richard J. Crout, The Drug Regulatory System: Reflections and
Predictions, 36 FOOD DRUG COsM. L.J. 106, 113 (1981).
"3 See 21 U.S.C. §§ 301-393 (1938).
14 Id. See also MARDEN DIXON & FRANK WOODSIDE III, 1 DRUG PRODUCT
LIABILITY: GOVERNMENT REGULATIONS § 8.01 (1997) (providing an overview
of the regulation of prescription drugs). The FDA oversees the process from the
initial testing of the product through post-marketing surveillance. Id. at 8-3. The
FDA also controls drug labeling, advertising and communications between
manufacturers and practitioners who prescribe pharmaceutical products. Id.
11 JAMES T. O'REILLY, 1 FOOD AND DRUG ADMINISTRATION: OVERVIEW
§ 13.01 (1995) (referring to 21 U.S.C. §§ 301-393). Marketers and manufacturers
of prescription drugs are primarily responsible for the safety and effectiveness
of the drug. Id. at 13-2. The FDA evaluates the empirical data provided by these
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about the risks and benefits of drugs should only be made with
caution. Accordingly, it is of import to note that drugs are different
than most other products because they have the potential to be
toxic.'6 Therefore, drugs deserve stricter governmental regulation.
From the time of the original Food, Drug & Cosmetic Act
("FDCA"), 17 legislation has always been intended to set standards
of quality while promoting technological advancement in the
development of new drugs. 8 Yet, as time passes, the problem of
"finding the proper balance between protecting and overburdening
the public" remains virtually unchanged.19
Initially, the Secretary of Agriculture had the primary respon-
sibility to investigate the safety of new drugs prior to entering
commerce.2° However, when Sulfanilamide was distributed
two entities to ascertain whether the drug is safe for human consumption. Id. at
13-2, 13-3. It is important to keep in mind that any and all procedures that are
designed to assess safety cannot guarantee a total absence of harm. Id. at 13-3.
16 See MARDEN DIXON & FRANK WOODSIDE III, 2 DRUG PRODUCT
LIABILITY: MANUFACTURERS LIABILITY § 14.01 (1997) (reviewing pharmaceuti-
cal agents). "[A] drug can cause a catastrophe even when the most elaborate
precautions known to medical science have been carefully followed." Id. at 14-2,
14-3.
17 Act of June 30, 1906, ch. 3915, 34 Stat. 768 (amended 1938). See also
O'REILLY, supra note 15, at 13-4 (noting that "the 1906 Act was superior to
scattered state and federal enactments which predated it, but by the time of the
New Deal it was evident that drug regulation required more explicit prohibitions
and broader powers of enforcement"); DIXON & WOODSIDE, supra note 14, at
8-5 (noting that the original FDCA "officially approved the prescription system
of drug distribution").
18 DIXON & WOODSIDE, supra note 14, at 8-4. As technological advance-
ments emerge, Congress seeks to protect the public. DIXON & WOODSIDE, supra
note 14, at 8-4. This desire may directly conflict with the ability to make more
drugs available to the public in a rather short time period. DIXON & WOODSIDE,
supra note 14, at 8-4.
"9 Cimons, supra note *, at A5 (noting that lawmakers, on one side, seek to
accelerate the approval process, while consumer groups, on the other, argue that
such accelerationwill inevitably weaken the FDA and ultimately leave the public
vulnerable to potentially dangerous pharmaceutical products).
20 See DIXON & WOODSIDE, supra note 14, at 8-5 (citing Act of June 25,
1938, ch. 675, § 1, 52 Stat. 1040).
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without ever being tested,21 more than one hundred people died
around the country.22 The resulting public outcry led to the
passage of the FDCA in 1938 which allowed for federal regulation
of new drugs.23 Pre-1938 drugs were generally recognized as safe
("GRAS") and did not require further clearance.24 All new drugs,
however, would require clearance by the FDA via a safety process
which was precipitated by the submission of a new drug application
by the drug manufacturer.25
By the early 1960's, it became clear that due to the sheer
number of prescription drugs which were inevitably accompanied
by potential for abuse in the face of technological advancement,
greater governmental control was needed.26 The 1962 amendment
to the FDCA additionally required proof of efficacy for all new
drugs.27 Prior to this amendment, the FDks role was simply to
2 Sulfanilamide is a diethylene glycol that was used as an antibiotic in the
mid-1930's. See DIXON & WOODSIDE, supra note 14, at 8-5. Diethylene glycol,
a substitute solvent, became a deadly poison when ingested in the doses recom-
mended by physicians. See O'REILLY, supra note 15, at 13-5.
22 Tests conducted by both the FDA and the American Medical Association
("AMA") thereafter showed that a few simple animal experiments would have
revealed the deadly solvent. See O'REILLY, supra note 15, at n. 15. The complete
report is available in MEMORANDUM OF SENATOR COPELAND ON INTRODUCTION
OF S1944 in C. DUNN, FEDERAL FOOD DRUG & COSMETIC ACT (1938).
23 See DIXON & WOODSIDE, supra note 14, at 8-5. The Secretary's
recommendation was to license control of new drugs to protect against general
distribution prior to experimental and clinical tests proving them safe and
effective. Id. See 21 U.S.C. §§ 301-393 (1938).
24 O'REILLY, supra note 15, at 13-6.
25 O'REILLY, supra note 15, at 13-6.
26 DIXON & WOODSIDE, supra note 14, at 8-6 (stating that Congress was
particularly concerned with the efficacy of numerous products marketed by the
pharmaceutical industry).
27 O'REILLY, supra note 15, at 13-7 (citing Pub. L. No. 87-781, 76 Stat. 780
(amending 21 U.S.C. §§ 321(p), 355 (1962)). See Jurow, Effect on the
Pharmaceutical Industry of "Effectiveness"Provisions, 19 FOOD DRUG COSM.
L.J. 110 (1964) (noting Senator Kefauver's objective was to insure that all drugs
are of adequate and acceptable quality, yet he conceded that the accomplishments
of the amendments were "relatively modest where the need is greatest"); S. REP.
No. 87-1744 (1962) (noting that the standard for both safety and effectiveness
requires that there be evidence consisting of adequate tests by all methods
reasonably applicable).
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perform a risk/benefit analysis whereby if the value of the drug
outweighed its potential risk, the FDA did not preclude the drug's
marketing.2"
Unfortunately, as a result of the AIDS crisis, drug product
approvals are once again on the "fast track." 29 Under President
Ronald Reagan's administration, there was minimal interference
with the drug market as evidenced by an ineffective regulation that
required Patient Package Inserts ("PPIs")30 to accompany most
commonly prescribed drugs.3' Manufacturers send PPIs to drug
prescribers in an effort to inform them of risks associated with the
drug's use.3' This action was applauded by the drug industry as
a barrier against intrusion into the practice of medicine. 33 How-
ever, FDA regulation becomes much more onerous when off-label
dispensing effectively serves to keep potential dangers well
hidden.34
The process by which a new drug is discovered involves
various elements of the unknown in understanding the pharma-
cology of a particular drug. A new drug is often heralded simply
by showing a desirable effect. An extensive experimental process
occurs in an effort to prove and to replicate the effect that was
28 DIXON & WOODSIDE, supra note 14, at 8-7. Furthermore, if a drug was
deemed innocuous prior to 1962, policy dictated that the FDA approve the
product even though its effectiveness could not be proven via scientific inquiry.
DIXON & WOODSIDE, supra note 14, at 8-7.
29 O'REILLY, supra note 15, at 13-8.
30 PPIs provide warnings directly to the users of the product about the
potential for the drugs to cause certain known adverse and serious side effects.
See 9 HEALTH NEWS DAILY 162, Aug. 21, 1997, available in WESTLAW, Health
& Medicine Database, HND File [hereinafter HEALTH NEWS DAILY]. This
procedure is used in addition to, not in place of, warnings on the drugs' labels.
Id.
"' See DIXON & WOODSIDE, supra note 14, at 8-11 (citing 47 Fed. Reg.
39,249 (1982)).
32 See HEALTH NEWS DAILY, supra note 30, at 162.
" DIXON & WOODSIDE, supra note 14, at 8-11.
14 See Langreth & Ingersoll, supra note 6, at B 1 (stating, in reference to fen-
phen, that the FDA "never approved the combined use of the appetite suppres-
sants because the health risks were unknown").
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originally observed." As more information develops, a New Drug
Application ("NDA") is filed with the FDA.3 6 Thereafter, it is the
FDAs obligation to oversee the process by which a new drug can
be marketed in interstate commerce. 7
A. New Drug Defined
All new drugs must have the following characteristics: (1)
classification as a drug; (2) absence of general recognition of safety
and efficacy for the drug or absence as to such recognition
regarding a particular use for which it is proposed to be used and
prescribed; and (3) absence of recorded pre-1938 uses for that drug
which match identically the uses for which the drug is now
represented to be useful.38 The FDA is given broad discretion in
determining whether these characteristics exist and a new drug can
be declared.39 For example, combinations of well-known drug
substances where such combinations have not become generally
recognized as safe and effective are included under the rubric of
new drugs.40 Absent sufficient evidence regarding efficacy of the
final product and a detailed report describing the tests employed to
assess the safety of the product, any change or introduction of a
new product must await FDA approval.4' Moreover, newness of
35 DIXON & WOODSIDE, supra note 14, at 8-13 (noting that scientists are not
only searching for that desirable effect, but also for any side effects and adverse
reactions which may occur).
36 DIXON & WOODSIDE, supra note 14, at 8-14. The FDCA provides that
"no person shall introduce or deliver for introduction into interstate commerce
any new drug, unless an approval application.., is effective with respect to
such drug." 21 U.S.C. § 355 (1938). Without the NDA, a potential competitor
cannot learn of clinical test results of a product; in turn, it cannot be marketed.
See also Edmund W. Kitch, The Patent System and the New Drug Application:
An Evaluation of the Private Investment in New Drug Research and Marketing,
in REGULATING NEW DRUGS 101 (Richard Landau, ed., 1973).
31 See DIXON & WOODSIDE, supra note 14, at 8-13.
38 Act of June 25, 1938, ch. 675, 52 Stat. 1040, 75th Cong., (1938).
39 DIXON & WOODSIDE, supra note 14, at 8-15 (noting that water may even
be construed as a drug when it is represented as having a curative effect).
40 S. Res. 194, 74th Cong., 2d Sess. (1937).
4 21 U.S.C. § 355(b)(1) (1962). The regulations establishing procedures for
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the drug's uses does not relate to past history; rather it relates to
the chemical composition which has not been recognized among
experts as safe and effective for a specific purpose.42 Essentially,
it is an expert decision to be made by the FDA subject to deferen-
tial judicial review.43 It has been held that the court cannot enter
the realm of FDA expertise and decide a product's safety and
efficacy because the FD/s superior expertise mandates deference
on factual issues. 44 Therefore, the courts broadly defer to the
implementation of 21 U.S.C. § 355 are at 21 C.F.R. §§ 312 and 314.
Any person may file with the Secretary an application with respect to
any drug . . . The application should include: (a) full reports of
investigations which have been made to show whether or not such drug
is safe for use and whether such drug is effective in use; (b) a full list
of the articles used as components of such drug; (c) a full statement of
the composition of such drug; (d) a full description of the methods
used in, and the facilities and controls used for, the manufacture,
processing and packing of such drug; (e) such samples of such drug
and of the articles used as components thereof as the Secretary may
require; and (f) specimens of the labeling proposed to be used for such
drug.
21 U.S.C. § 355(b)(1).
42 DIXoN & WOODSIDE, supra note 14, at 8-15.
4' Farquhar v. FDA, 616 F. Supp. 190, 193 (D.D.C. 1985). "The FDA has
the established procedures and expertise as well as the statutory authority to
make this difficult determination. Judicial review will of course be available at
a later time, but [an individual] must first exhaust his administrative remedies."
Id.
44 Premo Pharm. Labs, Inc. v. United States, 629 F.2d 795, 801 (2d Cir.
1980). New drug issues are "particularly suited to initial determination by the
FDA." Id. (quoting Weinberger v. Bentex Pharm., Inc., 412 U.S. 645, 653-54
(1973)).
Whether a particular drug is a "new drug," depends in part on the
expert knowledge and experience of scientists based on controlled
clinical experimentation and backed by substantial support in scientific
literature. One function is not peculiar to judicial expertise, the other
to administrative expertise. The two types of cases overlap and strongly
suggest that Congress desired that the administrative agency make both
kinds of determinations.




FDA's authority so that when a drug is reconstituted and declared
a new drug, courts generally agree.
B. Drug Categories
Products that become "drugs" are open to strict regulation by
the FDA. New drugs are divided into four statutory categories: (1)
articles recognized by the United States Pharmacopoeia and other
official formularies consisting of learned experts in the medical
field; (2) articles intended to be used in diagnosis, cure, prevention,
mitigation or treatment of disease in man or animals by chemical
action; (3) articles intended to affect the structure or any function
of the body of man or animals by chemical action; and (4) articles
intended to become a component of any of these three types of
articles.45 Categories 1,'2 and 3 contain both the finished drug
product and active ingredient components; category 4 includes the
active and inactive components of the drug.46 When determining
the statutory category of a new drug, the FDA and courts look to
the intent of the vendor.47 Throughout the process there is great
deference given to the FDA in reading such intent.4"
4' 21 U.S.C. § 321(g) (1994).
46 United States v. Generix Drug Corp., 460 U.S. 453, 454 (1983) (noting
that active ingredients in the majority of prescription drugs constitute only 10%
of the end product). For example, in treating hypertension, there are eight active
ingredients in chlorothiazide: allopurinol, spironolactone with hydrochlorothia-
zide, furosemide, diethylpropion hydrochloride, chlorothiazide with reserpine,
amitriptyline with perphenazine, prochloreperazine maleate, and chlorthalide. Id.
at 455.
47 United States v. Midwest Pharm. Inc., 825 F.2d 1238, 1246 (8th Cir.
1987) (concluding that the generic over-the-counterproducts were intended to be
sold as controlled substances). The drug in Midwest was advertised as "357
Magnum," "20/20," "30/30," "White Mole," "Mini-White" and "Incense." Id. at
1242. Midwest evinced knowledge that the practice of marketing or selling
misbranded drugs was apparent, endorsed and encouraged. Id. at 1247.
Furthermore, intent of this illegal activity was inferred via markings on the
capsules that were similar to that found on amphetamine capsules and quaaludes.
Id.
41 See generally Action on Smoking and Health v. Harris, 655 F.2d 236
(D.C. Cir. 1980). The court cited two rationales for deference on the administra-
tive interpretationof statutes-administrativeexpertise and congressional acquies-
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C. Experimental Procedures
The ability of the FDA to declare a product a "new drug" and
thereafter regulate it gives rise to a complex procedural system. The
first step is the pre-marketing investigation which involves animal
testing and various phases of clinical testing.49 Once a correlation
has been noted with a specific compound and a desired result, the
drug is tested on animals in an effort to avoid human exposure to
toxic materials.50 Common sense dictates that, with reasonable
exceptions, evidence of animal toxicity would serve as toxicity in
humans. Thus, animal testing determines the potential margin of
safety in humans at the preliminary stages of research.5
Clinical investigation is the next step in the FDKs process and
entails the administration of the drug to human subjects.52 This
step is comprised of three separate phases. Phase one recruits
volunteer human subjects in order to gain early information about
cence. Id. at 238.
41 DIXON & WOODSIDE, supra note 14, at 8-20.
S0 DIXON & WOODSIDE, supra note 14, at 8-20.
1 DIXON & WOODSIDE, supra note 14, at 8-13. See also 21 C.F.R.
§ 3 14.50(d)(2)(iv) (1985) (requiring a new drug application to include studies of
"the absorption, distribution, metabolism, and excretion of the drug in animals").
52 21 C.F.R. § 314.50 (d)(3). Clinical investigation means "any experiment
in which a drug is administered or dispensed to, or used involving, one or more
human subjects. For the purposes of this part, an experiment is any use of a drug
except for the use of a marketed drug in the course of medical practice." 21
C.F.R. § 312.3(b) (1987). The section, relating to human pharmacokinetics and
bioavailability, requires a description of the studies of the drug when adminis-
tered to humans. 21 C.F.R. §314.50 (d)(3)(i). Bioavailability has been defined
as "the degree to which a drug or other substance becomes available at the
physiological site of activity after administration." AMERICAN HERITAGE
COLLEGE DICTIONARY 139 (3d ed. 1993). Pharmacokinetics has been defined as
"the process by which a drug is absorbed, distributed, metabolized, and
eliminated by the body." AMERICAN HERITAGE COLLEGE DICTIONARY, supra,
at 1024. A statement of the analytical and statistical methods employed must
accompany the application, whether the studies were performed in compliance
with the institutional review board regulations and whether there was informed
consent on the part of the human subject. 21 C.F.R. § 314.50 (d)(3)(i).
806
FEN-PHEN
the product's pharmacological and pharmacokinetic effects.13
Phase two involves the dispensing of the drug to supervised
patients for the unique purpose of treating the disease for which it
was intended to determine the drug's safety and effectiveness.5 4
Phase three examines rarer side effects, drug efficacy and drug
interaction to better evaluate the overall risk-benefit relationship
and develop physician labeling.5
Upon completion of the clinical trials, the manufacturer must
submit an NDA to the FDA.16 The NDA is a compilation of all
the studies performed, including all noted benefits and adverse
effects of the products. 7 These reports must also contain an
affirmation that each study conducted was in compliance with
applicable regulations.58 The FDA requires all reports of clinical
tests to be attached to the NDA. 9 The FDA further mandates that
the NDA have copies of case reports annexed thereto for patients
who died or could not finish the testing due to adverse reactions.60
13 DIXON & WOODSIDE, supra note 14, at 8-21.
14 DIXON & WOODSIDE, supra note 14, at 8-21.
11 DIXON & WOODSIDE, supra note 14, at 8-22.
56 Each NDA submitted must contain a detailed summary of its contents as
set forth in 21 C.F.R. § 314.50(c). See 21 C.F.R. § 314.50(c) (1985) (requiring
that the summary include (1) the proposed text for labeling the drug; (2) the
pharmacologic class of the drug; (3) marketing history, if any, of the drug
outside of the United States; (4) chemistry, manufacturing and controls of the
application; (5) nonclinical pharmacology and toxicology; (6) human pharmaco-
kinetics and bioavailability; (7) microbiology for anti-infective drugs; (8) clinical
data; and (9) benefit and risk considerations). In addition, 21 C.F.R. § 314.50(d)
outlines the "technicalparts" of the NDA. See 21 C.F.R. § 314.50(d) (requiring
that the application contain "data and information in sufficient detail to permit
the agency to make a knowledgeable judgment about whether to approve the
application").
17 DIXON & WOODSIDE, supra note 14, at 8-22.
5" 21 C.F.R. § 314.50(d)(2)(v) ("For each nonclinical laboratory study, a
statement that it was conducted in compliance with the good laboratory practice
regulations [is required].").
'9 21 C.F.R. § 314.50(d)(3) (requiring a summary of the pharmacokinetics
and metabolism of the active ingredients).
60 21 C.F.R. § 314.50(f)(2) ("The application is required to contain copies
of individual case report forms for each patient who dies during a clinical study
or who did not complete the study because of an adverse event, whether believed
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In addition, an amendment to the NDA is available via an abbrevi-
ated application to correct any misinformation.6
Upon a showing that the drug is safe and effective for its
proposed use or uses, the NDA is approved by the FDA.62
However, such approval does not extend to other uses.63 There-
fore, a manufacturer is not permitted to promote a drug for a
purpose other than that approved.' 4 After approval, the manufac-
turer must file periodic briefs regarding ongoing clinical study of
the product. 65 Post-marketing requirements include an Alert report
to be filed within fifteen days of the time the manufacturer learns
of new side-effects.66 Moreover, a manufacturer must maintain
records concerning the safety and efficacy of the drug.67 Periodic
reports addressing studies in the medical and scientific literature
must also be filed.68 Once an adverse reaction associated with the
to be drug related or not.").
6' 21 C.F.R. § 314.54 (1992) (prohibiting approval of an abbreviated NDA
for a new indication and for other changes if investigations are necessary for
such approval).
62 DIXON & WOODSIDE, supra note 14, at 8-25.
63 DIXON & WOODSIDE, supra note 14, at 8-25.
64 DIXON & WOODSIDE, supra note 14, at 8-25.
65 See 21 C.F.R. §§ 310.303, 314.80 (1974). "The applicant must establish
and maintain records and make reports related to clinical experience or other data
or information necessary to make or facilitate a determination of whether there
may be grounds ... for suspending or withdrawing approval of the application."
21 C.F.R. § 310.303(a).
66 21 C.F.R. § 314.80(c)(1) (1985) ("The applicant shall promptly investigate
all adverse drug experiences that are the subject of these 15-day Alert reports and
shall submit follow-up reports within 15 working days of receipt of new
information or as requested by [the] FDA.").
67 21 C.F.R. § 314.80 ("The applicant shall maintain, for a period of 10
years, records of all adverse drug experiences known to the applicant, including
raw data and any correspondence relating to adverse drug experiences.").
6' 21 C.F.R. § 314.81. Such literature includes reports of experiences,
investigations or studies involving any property of the drug; copies of unpub-
lished reports regarding toxicological findings in animal studies and in vitro
studies; prepublication manuscripts conducted by the applicant; and published
clinical trials that include tabulations or summaries of the data. Id.
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use of the drug is noted, the manufacturer must file an FDA-1639,
Drug Experience Report.69
An NDA application will be approved by the FDA upon a
sufficient showing that the drug meets statutory standards for safety
and effectiveness, labeling, manufacturing and controls.70 It should
always be kept in mind that the FDA may refuse to approve an
NDA on the basis of insufficient information to determine if the
product is safe for use under the conditions prescribed.7' Upon
approval for marketing, the manufacturer has a continuing
obligation to monitor clinical experience with the drug and report
all adverse reactions to the treating physicians and the FDA.72
Often, warnings are to be inserted by the manufacturer in the
package insert and the Physician's Desk Reference.73 On other
69 21 C.F.R. § 314.80. Each form should refer to only one patient or a single
publication. 21 C.F.R. § 314.80 (f)(2). Copies of the FDA-1639 form may be
acquired from the Division of Epidemiology and Surveillance (HFD-730), Center
for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857. See 21 C.F.R. § 314.80(f)(4).
70 21 C.F.R. § 314.105(c) (1992) ("[The] FDA is required to exercise its
scientific judgment to determine the kind and quantity of data and information
an applicant is required to provide for a particular drug to meet the statutory
standards.").
" 21 C.F.R. § 314.125(b) (1985) (noting that the FDA may refuse approval
because of the absence of well-controlled investigations documenting that the
drug will indeed have its purported effect, inadequate labeling or improper
testing protocol).
72 21 U.S.C. § 355 (1962); 21 C.F.R. §§ 310.303, 310.305 (1986). "Each
manufacturer, packer, and distributor shall maintain for a period of 10 years
records of all adverse drug experiences required under this section to be reported,
including raw data and any correspondence relating to the adverse drug
experience .. " 21 C.F.R. § 310.305(f)(1).
71 See 21 C.F.R. § 201.56 (1979) (requiring that labels contain a summary
of scientific information, must be informative and accurate and shall be based,
whenever possible, on data derived from human experience); 21 C.F.R. § 201.57
(1979) (requiring that labels for human prescription drugs contain the following
information: (1) a "description" including the proprietary name, type of dosage,
pharmacological class and chemical name and structure of the formula; (2) a
"clinical pharmacology" section containing a summary of the clinical activity of
the drug in humans; (3) an "indications and usage" section requiring the label to
state that the drug is implicated in the treatment or prevention of a disease or
condition; (4) a "contraindications" section requiring the label to describe
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occasions, a "Dear Doctor" letter may be required.74 Furthermore,
the FDA Bulletin has proven a reliable source of information on
the approval of new drugs and the discovery of adverse reactions
with these drugs.75 If the danger is of such a magnitude that it
requires immediate withdrawal from the market, federal authorities
are empowered to suggest and negotiate such action.7
6
situations in which the drug should not be used; (5) a "warnings" section
requiring the label to state serious side effects and potential safety hazards; and
(6) a "precautions" section requiring the label to provide information addressing
special care guidelines, information for patients, laboratory tests, drug inter-
actions, pregnancy, pediatric use and geriatric use).
7 This letter is an advisory to the physician directly that adverse effects have
been noted with the drug's use. See DIXON & WOODSIDE, supra note 14, at
8-40.
71 DIXON & WOODSIDE, supra note 14, at 8-44. The FDA bulletin was
founded in 1971 by Dr. Henry E. Simmons, Director of the Bureau of Drugs.
DIXON & WOODSIDE, supra note 14, at 8-45. Dr. Simmons reasoned that since
physicians rarely saw the package inserts and heavily relied on information in
medical journal articles for their prescriptions, this would be the most effective
means of reaching and educating the physician about new drugs. DIXON &
WOODSIDE, supra note 14, at 8-45.
76 See 21 U.S.C. § 355(e).
The Secretary shall, after due notice and opportunity for hearing to the
applicant, withdraw approval of an application with respect to any drug
under this section if the Secretary finds (1) that clinical or other
experience, tests, or other scientific data show that such drug is unsafe
for use under the conditions of use upon the basis of which the
application was approved; (2) that new evidence of clinical experience,
not contained in such application or not available to the Secretary until
after such application was approved, or tests by new methods, or tests
by methods not deemed reasonably applicable when such application
was approved, evaluated together with the evidence available to the
Secretary when the application was approved, shows that such drug is
not shown to be safe for use under the conditions of use upon the basis
of which the application was approved; or (3) on the basis of new
information before him with respect to such drug, evaluated together
with the evidence that the drug will have the effect it purports or is
represented to have under the conditions of use prescribed, recom-
mended, or suggested in the labeling thereof; or (4) the patent
information prescribed [w]as not filed within thirty days after the
receipt of written notice for the Secretary specifying the failure to file
810
FEN-PHEN
The FDA also maintains extensive regulations concerning
current good manufacturing practice. 77 Specifically, a manufac-
turer must maintain records and establish production and control
procedures. 78 Furthermore, the manufacturer is also required to
keep a complaint file for one year after the expiration date of the
drug. 79 The intent is to provide authority to correct faulty opera-
tions prior to the production of defective drugs.80 Despite these
many stringent regulations, defective drugs inevitably find their
way into the drug market.8'
II. MANUFACTURER LIABILITY FOR PRESCRIPTION DRUGS
It is not surprising that the rise in the number of drug-related
injuries has led to a marked increase in litigation.82 The majority
such information; or (5) that the application contains any untrue
statement of material fact ....
Id.
17 21 C.F.R. §§ 210-211 (1978). For example, the regulations address
requirements with respect to personnel, equipment and components. 21 C.F.R.
§ 211.80.
7' 21 C.F.R. § 211.180. Additionally, all records must be made readily
available for authorized inspection at the establishment where the activities
described in the records takes place. 21 C.F.R. § 211.180(c).
79 21 C.F.R. § 211.180(b) ("Records shall be maintained for all components,
drug product containers, closures, and labeling for at least one year after the
expiration date .... "); 21 C.F.R. § 211.180 (e) ("Written records required by
this part shall be maintained so that data therein can be used for evaluating, at
least annually, the quality standards of each drug product to determine the need
for changes in drug product specifications or manufacturing or control
procedures.").
'o DIXON & WOODSIDE, supra note 14, at 8-51 (noting that a drug is deemed
adulterated "if the methods used in, or the facilities or controls used for, its
manufacture, processing, packing, or holding do not conform to or are not
operated or administered in conformity with current good manufacturing practice
to assure that such drug meets [the appropriate safety and quality standard]")
(citing THE CURRENT GOOD MANUFACTURING PRACTICE REGULATIONS (1963)
and section 501 (a)(2)(B) of the KEFAUVER-HARRIS DRUG AMENDMENTS
(1963)).
8 See DIXON & WOODSIDE, supra note 14, at 8-52.
s See Patty Coleman Selker, Note, An Escape from Strict Liability:
Pharmaceutical Manufacturers' Responsibility for Drug-Related Injuries Under
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of courts have held that in the case of pharmaceutical products, the
principle of strict liability is qualified by a special rule derived
from comment k to section 402A of the Restatement (Second) of
Torts. 3 Specifically, sellers of "unavoidably unsafe" products are
not held strictly liable to injured consumers as long as they warn
consumers of known or reasonably discoverable risks.84
Comment k provides that strict liability is not applicable to the
sale of a product that is incapable of being made safe for its
intended use so long as its utility outweighs its apparent risks and
Comment K to Section 402A of the Restatement (Second) of Torts, 23 DUQ. L.
REV. 199 (1984).
83 See, e.g., Brown v. Superior Court, 751 P.2d 470, 476 (Cal. 1988).
[C]omment k would impose liability on a drug manufacturer only if it
failed to warn of a defect of which it either knew or should have
known. This concept focuses not on a deficiency in the product-the
hallmark of strict liability-but on the fault of the producer in failing
to warn of dangers inherent in the use of its product that were either
known or knowable-an idea which "rings of negligence."
Id. The court further stated that
[T]here is an important distinction between prescription drugs and
other products such as construction machinery, the producers of which
were held strictly liable. In the latter case, the product is used to make
work easier or to provide pleasure, while in the former it may be
necessary to alleviate pain and suffering or to sustain life.
Id. at 478-79. Furthermore, public policy favors the development of new drugs
because the potential for the greater good far exceeds the risks that may
accompany the drug's introduction. Id. at 479.
4 RESTATEMENT (SECOND) OF TORTS § 402A cmt. k (1979).
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a warning is supplied. 5 Such products are labeled "unavoidably
unsafe." 6 While this term is not defined, all of the examples of
"unavoidably unsafe" products in comment k refer to prescription
drugs. 87 Therefore, a reasonable inference is that the drafters
intended to limit the scope of this provision to drugs and similar
products.8
Courts generally assume that the therapeutic benefits of
prescription drugs outweigh any risks associated with their use.89
For example, in Brown v Superior Court, a unanimous court
reasoned that since prescription drugs are products with indispens-
able uses, "a manufacturer is not strictly liable for injuries caused
by a prescription drug so long as the drug was properly prepared
and accompanied by warnings of its dangerous propensities that
85 Id.
[T]here are some products which, in the present state of human
knowledge, are quite incapable of being made safe for their intended
and ordinary use. These are especially common in the field of
prescription drugs.... [T]he seller of such products, again with the
qualification that they are properly prepared and marketed, and proper
warning is given, where the situation calls for it, is not to be held to
strict liability for unfortunate consequences attending their use, merely
because he has undertaken to supply the public with an apparently
useful and desirable product, attended with a known but apparently
reasonable risk.
Id.
86 W. PAGE KEETON ET AL., PROSSER AND KEETON ON THE LAW OF
TORTS 695 (5th ed. 1984) (hereinafter PROSSER & KEETON). See also Raymond
Paul Johnson & Mike Eidson, Product Liability History, in DEFECTIVE PRODUCT:
EVIDENCE To VERDICT § 1-40) (1995) (noting that "manufacturers need not
warn of dangers inherent in the use of unavoidably unsafe products because
theoretically these products cannot be made absolutely safe for intended uses,
even when properly prepared and accompanied by appropriate warnings").
87 See Richard C. Ausness, Unavoidably Unsafe Products And Strict
Products Liability: What Liability Rule Should Be Applied To The Sellers Of
Pharmaceutical Products?, 78 KY. L.J. 705, 714 (1990).
88 See Victor E. Schwartz, Unavoidably Unsafe Products: Clarifying The
Reasoning And Policy Behind Comment K, 42 WASH. & LEE L. REv. 1139, 1141
(1985).
89 See, e.g., DeLuryea v. Winthrop Lab., 697 F.2d 222, 228-29 (8th Cir.
1983); Basko v. Sterling Drug, Inc., 416 F.2d 417, 425-26 (2d Cir. 1969);
Gaston v. Hunter, 588 P.2d 326, 338-41 (Ariz. Ct. App. 1978).
813
JOURNAL OF LAW AND POLICY
were either known or reasonably scientifically knowable at the time
of distribution."9 Furthermore, "if drug manufacturers were
subject to strict liability, they would be reluctant to undertake
research programs to develop some pharmaceuticals that would
prove beneficial." 91
Once a drug is properly prepared and meets FDA approval, the
product cannot, as a matter of law, be "defective. 92 In Grundberg
v. Upjohn Co., the court opined that the benefits to society in
promoting the development, availability and reasonable price of
drugs justify this conclusion. 93 The court held that
90 751 P.2d 470, 482-83 (Cal. 1988).
9 Id. at 479 ("Public policy favors the development and marketing of
beneficial new drugs, even though some risks, perhaps serious ones, might
accompany their introduction, because drugs can save lives and reduce pain and
suffering.")
92 Grundberg v. Upjohn Co., 813 P.2d 89, 97 (Utah 1991). The court
acknowledged that by characterizing all FDA-approved prescription medications
as "unavoidably unsafe," it was inevitably expanding the literal interpretation of
comment k. Id. at 90. The court held that "a drug approved by the United States
Food and Drug Administration (FDA), properly prepared, compounded,
packaged, and distributed, cannot as a matter of law be defective in the absence
of proof of inaccurate, incomplete, misleading, or fraudulent information
furnished by the manufacturer in connection with FDA approval." Id. In strict
liability, the plaintiff need not impugn the conduct of the manufacturer or
retailer, but is required to impugn the product. See PROSSER & KEETON, supra
note 86, at 695. Defect is an element of strict liability whereby a plaintiff has to
establish that: (1) a defect in the product was a cause of the plaintiff s harm; and
(2) the product was defective when it left the hands of the defendant in order to
make out a prima facie case for liability. JAMES A. HENDERSON & AARON D.
TwERSKI, PRODUCTS LIABILITY: PROBLEMS AND PROCESS 17 (3d ed. 1997).
"The product must be defective in the kind of way that subjects persons or
tangible property to an unreasonable risk of harm." PROSSER & KEETON, supra
note 86, at 695.
13 813 P.2d at 96 (noting that "drugs are our most cost-effective input in
supplying the demand for health ... [and] if we are serious about minimizing
costs, our best bet is to increase the number of drug innovations").
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in light of the strong public interest in the availability and
affordability of prescription medications, the extensive
regulatory system of the FDA, and the avenues of recovery
still available to plaintiffs, [a] broad grant of immunity
from strict liability claims based on design defects should
be extended to FDA-approved drugs.94
Thus, according to the courts, comment k was intended to afford
a special protection to drug products and in so doing to limit the
scope of products liability.95
Many jurisdictions have applied comment k to cases involving
the liability of drug manufacturers, reasoning that it is counter-
intuitive to hold manufactures strictly liable for a failure to warn of
risks of which they were unaware and could not have been aware
of by the reasonable application of scientific knowledge available
at the time of distribution.96 Even if a new drug proves less
valuable than initially perceived, the manufacturer may still be
exempt from strict liability under comment k provided it was
unaware of the drug's risks.97 Therefore, a manufacturer that acts
94 Id. at 99.
9' Pollard v. Ashby, 793 S.W.2d 394, 406 (Mo. Ct. App. 1990). Although
holding that comment k provides only an affirmative defense for drug
manufacturers charged with a design defect, Judge Smith noted that "Comment
k therefore provides freedom from liability to prescription drugs where they are
properly prepared and adequate warnings are given. Such products are not under
those circumstances defective or unreasonably dangerous." Id.
96 See, e.g., DeLuryea v. Winthrop Lab., 697 F.2d 222, 228-29 (8th Cir.
1983) (noting that the standard for liability under strict liability and negligence
are essentially the same in the realm of drug products); McKee v. Moore, 648
P.2d 21, 24 (Okla. 1982) (noting that in the absence of FDA regulations to the
contrary, the manufacturer has no obligation to warn a consumer if the prescrib-
ing physician has been adequately warned of any adverse side effects); Chambers
v. G.D. Searle & Co., 441 F. Supp. 377, 380-81 (D. Md. 1975) (noting that
"[w]hile there may be a distinction drawn between a negligent failure to warn
and the warning requirements for strict liability insofar as other products are
concerned, comment k itself indicates that where new drugs, sold only under the
prescription of a physician, are involved, the standard is essentially the same").
97 See Gaston v. Hunter, 588 P.2d 326, 340 (Ariz. Ct. App. 1978)
(interpreting comment k to mean that for experimental drugs, the manufacturer
has a duty to explicitly advise that the drug is experimental and must warn of
known or knowable risks).
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reasonably in manufacturing and distributing an unavoidably unsafe
product will not be subject to strict liability for harm caused by this
product. 98
Drug manufacturers, however, sell knowledge as well as
products. 99 Therefore, the information that drug manufacturers
provide is of great importance. "A manufacturer of a prescription
drug has a legal duty to warn the medical profession, not the
patient, of any risks inherent in the use of the drug which the
manufacturer knows or should know to exist.'' °  However, a
violation of a duty to warn does not render the manufacturer liable
for injuries absent a showing that the product is defective.' A
manufacturer's duty is to adequately warn the attending physician,
but it has no duty to warn the lay public regarding prescription
" See Kociemba v. G.D. Searle & Co., 695 F. Supp. 432, 435 (D. Minn.
1988). "The manufacturer of a desirable yet unavoidably unsafe product is
protected in that it will not be held liable if it uses reasonable care in manufac-
turing an inherently dangerous product." Id. According to Minnesota Jury
Instruction Guide ("JIG") 117, "the reasonable care to be exercised by a
manufacturer when designing a product will depend on all facts and circum-
stances, including, among others, the likelihood and seriousness of harm against
the feasibility and burden of any precautions which would be effective to avoid
the harm." See JIG 117, MINNESOTA DISTRICT JUDGES ASS'N, MINN. PRACT.,
CIVIL (3d ed. 1986).
" Dixon & Woodside reason that many drugs are accompanied by
unavoidable dangers that may result in future complications. DIXON &
WOODSIDE, supra note 16, at 14-7. Therefore, drugs can be used safely only with
accurate and complete disclosure regarding safety and effectiveness from the
manufacturer. DIXON & WOODSIDE, supra note 16, at 14-7.
100 Smith v. E.R. Squibb & Sons, 273 N.W.2d 476, 479 (Mich. 1979) (citing
McEwen v. Ortho Pharm. Corp., 528 P.2d 522, 530 (Or. 1974)). See also
Sterling Drug, Inc. v. Yarrow, 408 F.2d 978, 991 (8th Cir. 1969); Love v. Wolf,
38 Cal. Rptr. 183, 184 (1964).
'0' Spuhl v. Shiley, Inc., 795 S.W.2d 573, 580 (Mo. Ct. App. 1990). A
necessary element of a strict liability claim under Section 402A is that the
product be in a defective condition. Id.; RESTATEMENT (SECOND) OF TORTS
§ 402A(1) (1979). "A product is in a defective condition where the condition is
one not contemplated by the ultimate consumer, which condition caused the
product to fail to perform in the manner reasonably to be expected in light of its
nature and intended fimction." Richardson v. Holland, 741 S.W.2d 751, 754 n.3




drugs. 10 2 Furthermore, there is a continuing duty on the part of
the manufacturer to provide post-sale warnings to physicians of any
deficiencies that it learns exist in the product. 3
The duty to warn of drug dangers is particularly important
because drug dangers are not open and obvious.' A manufac-
turer is deemed an expert in his/her particular field and is under a
continuous duty to keep abreast of scientific developments relating
to the manufacturer's product and to notify the medical profession
of any additional adverse effects discovered from its use1 °5
102 Pierluisi v. Squibb, 440 F. Supp. 691, 694 (D.PR. 1977). It is the
prevailing general rule that the duty to adequately warn of a drug's propensity
for harm is discharged by a manufacturer's warning to doctors. Id. See also
Parke Davis & Co. v. Stomosodt, 411 F.2d 1390, 1401 (8th Cir. 1969) (noting
that the warning should be sufficient to appraise a general practitioner of the
dangerous propensities of the drug); Gravis v. Parke Davis & Co., 502 S.W.2d
863, 870 (Tex. Civ. App. 1973) (finding that it is unreasonable to demand that
the manufacturer of drugs specifically warn each and every patient that receives
drugs prescribed by the physician or other authorized persons).
103 See, e.g., Braniff Airways, Inc. v. Curtiss-Wright Corp., 411 F.2d 451,
453 (2d Cir.), cert. denied, 396 U.S. 959 (1969).
It is clear that after such a product has been sold and dangerous defects
in design have come to the manufacturer's attention, the manufacturer
has a duty either to remedy these or, if complete remedy is not
feasible, at least to give adequate warnings and instructions concerning
methods for minimizing the danger.
Id.
104 Tampa Drug Co. v. Wait, 103 So. 2d 603, 607 (Fla. 1958).
When a distributor of an inherently dangerous commodity places it in
the channels of trade, then by the very nature of his business, he
assumes the duty of conveying to those who might use the product a
fair and adequate warning of its dangerous potentialities to the end that
the user, by the exercise of reasonable care on his own part, shall have
a fair and adequate notice of the possible consequences of use or even
misuse.
Id.
'05 McEwen v. Ortho Pharm. Corp., 528 P.2d 522, 528 (Or. 1974) (citing
Schenebeck v. Sterling Drug Inc., 423 F.2d 919, 922 (8th Cir. 1970)). "To
satisfy this duty, the manufacturer must utilize methods of warning which will
be reasonably effective, taking into account both the seriousness of the drug's
adverse effects and the difficulties inherent in bringing such information to the
attention of a group as large and diverse as the medical profession." Id. at 529.
JOURNAL OF LA W AND POLICY
Therefore, the issue becomes "whether the manufacturers met their
duty of promulgating warnings commensurate with their actual
knowledge gained from research and adverse reaction reports as
well as commensurate with their constructive knowledge as





FDA regulations require only that package inserts, the advertis-
ing and the labeling be changed when a new defect has been
discovered,1 7 and adverse experiences be reported promptly.'0 8
The FDAs concern is purely regulatory in nature. However, there
is no implication that a manufacturer is strictly liable for failure to
warn the medical community of possible injury absent a showing
of proximate causation that an adequate warning would have pre-
vented the injury.1 09 If such injury has never occurred before and,
106 Dalke v. Upjohn Co., 555 F.2d 245, 248 (9th Cir. 1977).
107 See 21 C.F.R. § 201.57 (1979). The label must state the limitations
associated with a particular drug's use. 21 C.F.R. § 201.57(3)(i). If the drug
should be reserved for certain situations, this information shall also be stated in
the labeling section. 21 C.F.R. § 201.57(3)(ii). If indications for long term use
are different from that of short term use, the label shall specifically assert such.
21 C.F.R. § 201.57(3)(iii).
108 See 21 C.F.R. § 314.80(a) (1985).
Adverse drug experience means any adverse event associated with the
use of a drug in humans ... including the following: an adverse event
occurring in the course of the use of a drug product in professional
practice; an adverse event occurring from drug overdose, whether
accidental or intentional; an adverse event occurring from drug abuse;
and adverse event occurring from drug withdrawal; and any failure of
expected pharmacological action.
Id.
109 See, e.g., Stanback v. Parke, Davis & Co., 657 F.2d 642, 644-45 (4th Cir.
1981) (noting that there is a distinction between a failure to warn case in which
the physician might have responded to a warning and one in which he would not
have done so because in the former there is evidence of causation); Chambers v.
G.D. Searle & Co., 441 F. Supp. 377, 385 (D. Md. 1975) (finding that adequate
warnings associated with the use of oral contraceptives would not have affected
the physician's treatment of the patient and therefore lacked causation); Vaughn
v. G.D. Searle & Co., 536 P.2d 1247, 1251 (Or. 1975) (finding no proof of
causation because even if the physician had been properly warned, the patient
would have been treated in the identical manner).
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with the exercise of due care, the manufacturer could not have
foreseen such an injury, there can be no duty to warn."'
A manufacturer is not liable for the "unfortunate consequences
attending use of a prescription drug merely because the manufac-
turer had undertaken to supply the public with an apparently useful
and desirable product, attended with a known but apparently
reasonable risk.""' Accordingly, if the manufacturer gives proper
warnings of potential hazards of the drug and the warnings are read
by a prescribing physician, "the company has fulfilled its duty and
there is no liability."' 1 2 Moreover, there can be no liability if the
prescribing physician relies on his own knowledge when prescrib-
ing a drug. 113 Therefore, similar to the act of firing a loaded
weapon in a crowded room, liability must fall on the physicians
who are dispensing off-label drug combinations absent adequate
empirical evidence regarding safety, because someone will surely
be harmed.
III. THE FEN-PHEN COCKTAIL
Under current FDA statutes, drug manufacturers cannot
distribute off-label information because it is considered illegal
0 See Johnston v. Upjohn Co., 442 S.W.2d 93, 97 (Mo. Ct. App. 1969).
"'One factor which conditions the taking of precaution is the knowledge or
means of knowledge of the danger. If the maker is justifiably ignorant of a
danger in his product there is no negligence in a failure to guard against it."' Id.
(quoting 2 FOWLER V. HARPER & FLEMING JAMES JR., THE LAW OF TORTS,
§ 28.7 (1956)).
.. Demmler v. SmithKline Beecham Corp., 671 A.2d 1151, 1155-56 (Pa.
Super. Ct. 1996). The law requires a reasonable connection between the act or
omission on the part of the manufacturer and the injury suffered by the
complainant. Id.
'2 Parke, Davis & Co. v. Mayes, 183 S.E.2d 410, 410 (Ga. Ct. App. 1971).
The court held that the manufacturers of Chloromycetin gave a sufficient warning
to the medical profession regarding the possibility of causing anemia. Id. The
prescribing doctor read the warnings and was made aware of possible dangers
associated with the drug's use. Id. Accordingly, the company fulfilled its duty.
Id.
113 See Formella v. Ciba-Geigy Corp., 300 N.W.2d 356, 358 (Mich. Ct. App.
1980) (noting that the physician knew that Tandearil could cause blood dyscrasia
after prolonged use but failed to conduct a blood test prior to dispensation).
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promotion. 14 Physicians, though, are free to prescribe approved
drugs for off-label purposes without the protection of long-term
studies and FDA approval for the new use."' This freedom is
particularly dangerous with respect to diet drugs due to the
willingness of society to try anything to find the "magical relief'
for obesity."16 Coupling such a desire with a physician's unfet-
tered prescription tactics relegates fen-phen to be labeled an
inevitable tragedy.
A. Obesity As A Major Public Health Concern
Obesity is a harmful condition and a major public health issue.
Obesity is the most common and costly nutritional problem in the
United States, affecting approximately thirty-three percent of
adults." 7 However, the vast amount of money spent in an effort
to lose weight is often for naught because the weight is usually
gained back. 1 8 Weight reduction strategies such as food restric-
114 See Cimons, supra note *, at A5.
... See Cimons, supra note *, at A5 ("Doctors appropriately rely on journal
articles all the time, but there are two problems associated with [relying on small
studies]: Companies lose the incentive to do the [larger] studies and, occasion-
ally, you'll have a medical disaster.").
116 See James J. Cerda, M.D., The Pharmacologic Management of Obesity,
84 J. FLA. MED. ASS'N 89 (1997). The article concluded that: (1) obesity is not
cosmetic; (2) the weight loss industry is lucrative and must be watched closely;
and (3) until the FDA revises labeling and until long-term studies are available,
the use of unapproved anorectic medications for extended periods of time must
be presented to the patient in such a manner so that he or she is made aware that
the drug is unapproved and still in its investigational phase. Id. at 91.
117 R.J. Kuczmarski, et al., IncreasingPrevalenceofOverweightAmong U.S.
Adults, 272 JAMA 205, 205-11 (1994). See also Robert M. Russell, Nutrition
(contempo), 277 JAMA 1876, 1876 (1997) (noting that The National Health and
Nutrition Examination Survey, a cross-sectional sampling of surveys that are
performed periodically and provide national health reference data, found that
Americans gained an average of 3.6kg [approx. 7.9 lbs.] between 1980 and 199 1,
with an eight percent increase in the prevalence of obesity).
"I' T.A. Wadden, Treatment of Obesity By Moderate and Severe Caloric
Restriction: Results of Clinical Research Trials, 229 ANNALS OF INTERNAL MED.
688, 688-93 (1993). Ninety to ninety-five percent of persons who lose weight
subsequently regain it. Id. Furthermore, health care costs attributable to obesity
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tion, exercise and behavior modification are well established
treatments for the obese population. The obesity problem arises,
however, because these weight reduction practices have very poor
long-term outcomes attributable primarily to a lack of compli-
ance.
119
The chronic nature of obesity coupled with the prevalent
perception of lack of willpower, laziness and inferiority that
accompanies the disease makes the treatment frustrating. 120
Literature has shown that obese people are often referred to as
"morally defective" and "gluttonous," making weight management
suspect at reputable institutions.'2 ' Many patients accept the myth
amount to approximately $68 billion per year, and an additional $30 billion per
year is spent on weight-reduction programs and special foods. Id. See also Long-
term Pharmacotherapy in the Management of Obesity: National Task Force on
the Prevention and Treatment of Obesity, 276 JAMA 1907, 1907-15 (1996);
Danya Harpster, What Have You Got To Lose?, NEW ORLEANS TIMES, Oct. 14,
1997, at Fl.
A dieter invests money and time, whether he or she enrolls in a Weight
Watchers group, is one of the estimated 8 million people who annually
buy into a commercial diet program such as Jenny Craig - with its
frozen food, vitamins and walking tapes- or simply plunk down $12.95
for the Sugar Busters book and overhaul the pantry.
Id.
19 B. Guy-Grand, Pharmacological Approaches to Intervention, 21 SUPP. 1
INT'L J. OF OBESITY & RELATED METABOLIC DISORDERS S22 (1997). Studies
have shown that pharmacotherapy, combined with classical treatment strategies,
have improved the long-term maintenance of weight loss. Id. at S24. "Pharmaco-
therapy appears to be the key to effective anti-obesity therapy. Drugs have utility
for inducing weight loss in refractory obesity when classical techniques have
failed. Drugs also have [the] potential for preventing regain of weight, so aiding
long-term maintenance of weight loss." Id.
20 Russell, supra note 117, at 1876. This stereotype is based on the assertion
that so many people are trying to lose weight, but so few engage in the
recommended amount of at least 30 minutes of physical activity that raises the
heart-rate for at least four days per week. Russell, supra note 117, at 1876. Not
only does exercise burn calories, but it also reduces the likelihood of obesity-
related conditions such as heart disease and high blood pressure. Russell, supra
note 117, at 1876.
121 Cerda, supra note 116, at 89 (noting that many physicians avoid obesity
treatment as part of their practice for fear of being labeled "quacks" and that
"pandering to patients' desires with anorectic medications automatically renders
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that obesity is "a social disease and live in shame and frustration." 122
Hence, it is not surprising that "[s]truggling dieters may be willing
to take the risk of unlikely and unconfirmed ailments in exchange
for a sure way to lose weight."'2'  Recently, the "traditional
methods of weight loss, involving a decrease in caloric intake,
increase in exercise, and behavior modification" have been
expanded to include the concept of pharmacologic management of
obesity. 24
B. The Creation of Fen-Phen
For decades, appetite-suppressant drugs have cycled in and out
of popularity with the medical profession and patients alike, each
group desperate for treatment answers. "Current evidence suggests
that drugs for the treatment of obesity, either alone or in combina-
tion, may produce short-term weight loss. ' ' t25 Hailed as a major
a clinician as a second class practitioner").
122 Cerda, supra note 116, at 90. Obesity is defined as a "body mass index"
("BMI") greater than 27 where the weight is expressed in kilograms and height
in meters. Cerda, supra note 116, at 90. The BMI is the weight in kilograms
divided by the square of the height in meters. Cerda, supra note 116, at 90.
Often the cause of obesity is dismissed as the patient's compulsive eating
lifestyle. Cerda, supra note 116, at 90. While this habit aggravates obesity,
psychiatric and biological infumities play an equally important role. Cerda, supra
note 116, at 90.
123 Laura Fraser, The New Diet Drugs, They Really Do Help Some People
Lose Weight: But Are They Worth the Risk?, 10 HEALTH 52 (1996). However,
fen-phen has not proven more effective than other diet regimens. In the
Weintraub study, only 26 out of the 121 patients lost more than 10% of their
body weight from taking fen-phen. See Weintraub, infra note 130, at 581-646
(revealing that the risks outweigh the potential benefits). Furthermore 19 dieters
dropped out of the study because of side effects. Weintraub, infra note 130, at
581-646. Lastly, none of the patients maintained the weight loss once off the fen-
phen "cocktail." Weintraub, infra note 130, at 581-646.
124 Cerda, supra note 116, at 90 (stating that diet drugs act centrally,
peripherally, or via a combination of these methods).
125 Eugene V. Biosaubin, Treatmentfor Obesity, 276 JAMA 445,445 (1996).
However, the National Institute of Health called for additional long-term studies.
Id. A weight-loss regimen should include exercise and behavior modification. Id.
A "mission statement" should also be established setting reasonable, attainable
822
FEN-PHEN
advance for managing obesity, fen-phen seemed to be a panacea for
people who are thirty percent above their ideal weight.'26
It was hypothesized that fenfluramine combined with phenter-
mine would enhance weight loss over and above what could be
achieved with the best behavior modification, exercise and nutrition
program. 12 Accordingly, in a 1992 medical study, Dr. Weintraub,
a professor of clinical pharmacology at the University of Rochester,
administered the combination of fenfluramine at sixty milligrams
and phentermine at fifteen milligrams in addition to behavior
modification for 190 weeks in 121 obese females. 28 This combi-
nation drug therapy resulted in significant weight loss sustained
over 210 weeks. 129  Weintraub and coworkers, 30  (fellow
researchers and pharmacologists) concluded that anorexiant
medications 3' can help one lose weight and maintain the weight
goals for the individual. Id.
126 4 HARVARD WOMEN'S HEALTH WATCH, Feb. 1997, available in
WESTLAW, Health & Medicine Database, HVD-WHW File [hereinafter
HARVARD WOMEN'S HEALTH WATCH]. However, "[b]ecause the drugs are used
to treat a condition that affects 58 million people, experts are concerned that
indiscriminate use of these medications will lead to an increase in the number of
people who suffer serious and potentially fatal side effects." Id.
127 See M. Weintraub et al., Long-term Weight Control Study: I-VII, 51
CLINICAL PHARMACOLOGY & THERAPEUTICS 581-646 (1992).
12 See Cerda, supra note 116, at 90-91 (noting that "[a]s expected, when the
drugs were stopped in some patients they slowly regained weight despite
continued diet, exercise and behavior modification"). Other patients, who were
administered fen-phen on an intermittent basis, lost weight while on the
medication and increased weight while not on the medication. Cerda, supra note
116, at 91. Hence, the implication is that treatment for obesity, similar to other
chronic diseases, should be continuous. Cerda, supra note 116, at 91.
129 Cerda, supra note 116, at 90.
13o These researchers reasoned that patients might obtain better results and/or
have fewer side effects if sub-maximal doses of a drug from each group were
combined in a study. M. Weintraub et al., Long-term Weight Control Study:
I- VII, 51 CLINICAL PHARMACOLOGY & THERAPEUTICS 581-646 (1992). Further-
more, the drugs might act synergistically to produce a positive effect on weight
loss. Id. In addition, using two drugs with opposing adverse side effects might
potentially offset each other and result in a lower incidence of both. Id.
' Anorexiant is defined as "producing anorexia." 1 THE NEW SHORTER
OxFoRD ENGLISH DICTIONARY 83 (1993). Anorectic means "characterizedby a
lack of appetite." Id.
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loss for prolonged periods of time with little fear of developing
abuse patterns associated with drug ingestion. 3 2 This study
proved to be the beginning of a craze that would end with many
questioning how physicians could prescribe such a drug with little
empirical data to support such dispensing.
Fenfluramine (Pondimin),'33 a serotinergic agent, 13 4 acts to
'32 For example, drug addiction is a serious and widespread problem facing
prescription drug users. See NEIL R. CARLSON, PHYSIOLOGY OF BEHAVIOR 582
(5th ed. 1994). Similar to the use of "designer drugs," users of off-label
prescription drugs are exposed "to unknown dangers of untested and often
contaminated products." Id. at 583.
13' Fenfluramine is manufactured by A.H. Robins, a subsidiary of American
Home Products, Inc. See ANDREWS PHARMACEUTICAL LITIGATION REPORTER
12321 (June 1997). See also Paul D. Rheingold, Fen-Phen/Redux Diet Drugs,
MEALEY'S LITIGATION REPORTS: DRUGS AND MEDICAL DEVICES, Aug. 1, 1997,
at 22 (noting that "fen" is sold under a number of trade names by A.H. Robins,
a subsidiary of American Home Products, Inc).
134 A neurotransmitter is an "endogenous chemical released by one neuron
that alters the electrical activity of another neuron." See ROBERT M. JULIEN,
M.D., PH.D., A PRIMER OF DRUG ACTION: A CONCISE NONTECHNICAL GUIDE
To THE ACTIONS, USES, AND SIDE EFFECTS OF PSYCHOACTIVE DRUGS 495 (7th
ed. 1995). At the most basic level, the brain cannot process information without
neurotransmitters. Michael D. Lemonick, The Mood Molecule Serotonin Drugs
Treat Everything From Depression To Overeating, But As We Learned Last
Week, Tinkering With The Chemistry Of The Brain Can Be Risky, TIME, Sept. 26,
1997, at 74. This situation exists because neurons are separated by gaps
(synapses). Id. The communication process is as follows: an electrical impulse
is released into the nervous system. Id. This "signal" reaches the "home" of the
neurotransmitters (vesicles) and the neurotransmitters are released. Id. These
chemicals navigate across the synapse and lock into receptors. Id. The locking
in at postsynaptic receptors produces "an action equivalent to flipping on a light
switch." Id. That is "the locations in the nervous system at which a neurotrans-
mitter or drug binds to exert its characteristic effect." JULIEN, supra at 496. The
neurotransmitters are then reabsorbed or destroyed. Lemonick, supra, at 74.
Serotonin is a special neurotransmitter in that it gives the message "an emotional
tone." Lemonick, supra, at 74. "A person's mood is like a symphony and
serotonin is like the conductor's baton." Lemonick, supra, at 74.
Fenfluramine is structurally related to amphetamine but acts on serotonin as
opposed to norepinephrine. JULIEN, supra, at 150. As a serotinergic agent,
fenfluramine prevents this neurotransmitter from leaving the synaptic cleft and,
therefore, the chemical remains in the bloodstream longer and creates a
prolonged reaction. JULIEN, supra, at 150. This results in a heightened response,
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"partially inhibit reuptake of serotonin (5-HT) and to release 5-HT
from nerve endings. This increased 5-HT in the synaptic cleft is
believed to indirectly reduce food intake [by evoking a feeling of
satiety]."' 35 "Serotonin is an inhibitor of activity and behavior"
particularly involved in the functions of "sleep, wakefulness, mood,
temperature regulation, feeding, and sexual activity.' 36 The
action of fenfluramine has not been clearly defined. It appears that
by inhibiting the reuptake of serotonin, fenfluramine "increase[s]
fat mobilization, decrease[s] absorption of dietary fat, and
increase[s] cellular glucose uptake., 137 Additionally, the medica-
as evidence through mood, physiology and behavior. JULIEN, supra, at 150. Drug
molecules must attach to specific receptors (like a lock and key relationship)
which thereby change the functional property of the cell and produce a
pharmacological response. JULIEN, supra, at 36. See also CARLSON, supra note
132, at 72-73.
[M]olecules of the transmitter substance are destroyed by an enzyme
or taken back into the terminal button through the process of reuptake.
Drugs can interfere with either of these processes; because they
prolong the presence of the transmitter substance in the synaptic cleft
(and hence in a location where they can stimulate postsynaptic
receptors).
CARLSON, supra note 132, at 72-73.
13' G.A. Bray, Use and Abuse of Appetite-Suppressant Drugs in the
Treatment of Obesity, 119 ANNALS OF INTERNAL MEDICATION 708-09 (1993).
A blockade of reuptake results in an agonist action whereby the neurotransmitter
spends a greater amount of time available for interaction with postsynaptic
receptors. Id. at 708. See generally PDR, supra note 7, at 1288-89 (finding that
the action of such drugs in treating obesity is primarily one of appetite suppres-
sion).
136 JULIEN, supra note 134, at 479. In the brain, "significant amounts of
serotonin are found in the upper brain stem, with a large collection in the pons
and medulla." JULIEN, supra note 134, at 479. "Other neurotransmitters help us
know our stomachs are full; serotonin tells us whether we feel satisfied. Other
chemicals help us perceive the water level in a glass; serotonin helps us decide
whether we think of it as half empty or half full." Lemonick, supra note 134, at
74.
131 SeeAMERICAN HOSPITAL FORMULARY SERVICE: FENFLURAMINE HYDRO-
CHLORIDE, GAS REGISTRY No: 404-82-0, American Society of Health Systems
PHA (1997) [hereinafter FORMULARY SERVICE- FENFLURAMINE] (on file with
Journal of Law and Policy). Fenfluramine hydrochloride is a "white, crystalline
powder and is soluble in water." Id. Its appetite-inhibiting action most likely
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tion is thought to relieve hunger by altering nerve impulses to the
appetite control center of the brain. 138
Phentermine (Ionanmin)'39 is an amphetamine-like drug,"4
used as an anorexigenic agent, which is secondary to cetral nervous
system stimulation. 14 1 More specifically, phentermine inhibits the
uptake of norepinephrine (Ne)142 and dopamine (Da).143 Essen-
results from stimulation of the ventromedial nucleus of the hypothalamus. Id.
The hypothalamus is involved in visceral and autonomic changes along with the
regulation of hormonal release. Id.
138 CONSUMER GUIDE TO PRESCRIPTION DRUGS: THE MOST COMPLETE,
AUTHORITATIVE, AND CURRENT BOOK OF ITS KIND 169-70 (1990) [hereinafter
CONSUMER GUIDE]. Fenfluramine's effectiveness lasts only for short periods of
time (3-12 weeks). Id. at 169. Treatment involves taking the drug "with a full
glass of water one hour before meals." Id. Side effects include blurred vision,
constipation, diarrhea, dizziness, dry mouth, euphoria, fatigue, insomnia,
irritability, nausea, nervousness, restlessness, stomach pain, sweating, unpleasant
taste in the mouth and vomiting. Id. at 170.
139 Phentermine is sold under various trade names including Fastin, Apidex,
Obe-Nix and Ionamin. See CONSUMER GUIDE, supra note 138, at 326. Numerous
manufacturers are involved in the sale of this drug. See CONSUMER GUIDE, supra
note 138, at 326.
'40 Amphetamines act as behavioral stimulants. JULIEN, supra note 134, at
489. Similar to the action of cocaine, amphetamines block the reuptake of
dopamine, which is the neurotransmitter implicated in movement, attention and
learning. CARLSON, supra note 132, at 585.
141 See AMERICAN HOSPITAL FORMULA SERVICE: PHENTERMINE HYDRO-
CHLORIDE, CAS REGISTRY NO: 122-09-8, American Society of Health Systems
PHA (1997) [hereinafter FORMULARY SERVICE- PHENTERMINE] (on file with
Journal of Law and Policy). Phentermine is available as a "hydrochloride salt
and as a cation exchange resin complex of sulfonated polystyrene." Id. It is used
as an adjunct to caloric restriction in the short-term treatment of obesity. Id.
Phentermine is designed to be most effective in controlling appetite during the
first few weeks of dieting. CONSUMER GUIDE, supra note 138, at 326. The drug
is also available in a time-release form which must be swallowed whole or side
effects may increase. CONSUMER GUIDE, supra note 138, at 326. The side effects
are almost identical to that of fenfluramine with the addition of a false sense of
well-being. CONSUMER GUIDE, supra note 138, at 327.
42 CARLSON, supra note 132, at 64. Produced in the adrenal glands, this
neurotransmitter is primarily involved in alertness and wakefulness. CARLSON,
supra note 132, at 65.
143 FORMULARY SERVICE- PHENTERMINE, supra note 141. The cell bodies of
Ne are located in the brain stem. JULIEN, supra note 134, at 477. Large amounts
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tially, among other things, phentermine "indirectly suppresses
appetite by inhibiting Da receptors."'44
C. Problems With The "Fen-Phen Cocktail"
Off-label dispensing of drugs cannot become an uncontrolled
experiment on millions of Americans. Yet it is evidently becoming
an invitation for people to self-medicate in an effort to shed a few
pounds. One problem that immediately developed from the
dispensing of fen-phen was the number of prescriptions written for
people of lesser girth.1 41 One reason for this is that local Nutri/-
System weight-loss centers highlight the fact that a physician will
give a quick check-up and then a prescription for diet pills.
46
More astonishingly, one can just log on to the internet and get a
of Da are found in the basal ganglia, the frontal cortex and the limbic system.
JULIEN, supra note 134, at 478. "The release of Ne produces an alerting,
focusing, orienting response (similar to the fight/flight/fright syndrome)" and
"positive feelings of reward." JULIEN, supra note 134, at 478. The release of Da
is associated with emotion and reward systems. JULIEN, supra note 134, at
478-79.
'" Cerda, supra note 116, at 90 (noting that as the length of time that a
person is on the drug increases, the effect on weight decreases).
145 HARVARD WOMEN'S HEALTH WATCH, supra note 126. The number of
prescriptions written for fen-phen increased from 60,000 in 1992 to 1.1 million
by 1995. HARVARD WOMEN'S HEALTH WATCH, supra note 126. Patients
received 18 million new prescriptions and refills last year alone. See Heart
Disease: Valvular Heart Disease Associated With Commonly Prescribed Diet
Pills, BLOOD WEEKLY, July 28, 1997, available in 1997 WL 10931944 [herein-
after BLOOD WEEKLY].
146 Fraser, supra note 123, at 52. Last fall Nutri/System became the first
major diet center in the country to give clients appetite suppressants under a pilot
program referred to as NutriRx. Fraser, supra note 123, at 52. When asked what
she would do if the NutriRx doctor stopped prescribing fen-phen for her, a
patient responded, "I'll just find another center and another doctor." Fraser, supra
note 123, at 52.
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prescription for fen-phen. 147 Dr. Pietr Hitzig advertises on the
web that if you cannot make it to his office, he will prescribe drugs
via other means. 48 Despite little training in obesity, many physi-
cians have begun overnight fen-phen treatment programs with
promises of a more slender you that will not fade in time.' 49
Certainly, one can find safer and more effective means for such
a serious health problem. "The bottom line is what have diet pills
produced other than hundreds of millions of dollars of sales and
hundreds of thousands of adverse events a year?"' 0 A quick
glimpse into current litigation makes this statement far more
alarming: Thomas and Mary Linnen contend that their thirty-year-
old daughter died because of primary pulmonary hypertension as a
direct result of using fen-phen.' 5' Additionally, in a class action
complaint, plaintiffs seek to represent persons nationwide who have
147 See, e.g., Pietr Hitzig, The Fen/Phen Protocol: Frequently Asked
Questions(lastmodifiedMayl O, 1996)<http://techno.king.net/jmay/faq.txt.html>.
14' Kolata, supra note 1, at A3. "Pietr Hitzig, M.D., an internist, had
practiced general medicine for 20 years before devoting himself to the exclusive
treatment of patients using the Fen/Phen protocol." Pietr Hitzig, The Fen/Phen
Protocol: Frequently Asked Questions, (last modified May 10, 1996) <http://tech-
no.king.net/jmay/faq.txt.html>.
149 Kushner, supra note 10, at 603. These physicians have seized on the drug
frenzy that has been revered in magazines and tabloids and have made it a
profitable enterprise. A Chicago program featuring fen-phen in a newspaper
advertisement offered patients half-off on the first visit merely "as an incentive
to try the program." Kushner, supra note 10, at 603. As a result of adver-
tisements such as this, sales for phentermine have increased 442% and sales for
fenfluramine are up 6,390%. Kushner, supra note 10, at 603. "Like a palooka
prizefighter, the pharmaceutical industry keeps coming at overweight Americans
with one basic strategy ... [a]ppetite suppression." See Rick Ansorge, Experts
Call Appetite-Suppressing Drugs Sure Losers, CINCINNATI ENQUIRER, Oct. 17,
1997, at D02.
IS' Tiedt, supra note 2, at 1201. "Diet pills are at best only signals to stick
to required diet and exercise. Certainly, we can find safer and more effective
signals for such a serious health problem. The use of these drugs only adds to the
unhealthy societal attraction to synaptic stimulants." Tiedt, supra note 2, at 1201.
151 SeefHighlights, ANDREWS PHARMACEUTICAL LITIGATION REPORTER, June
1997, at 12321. (noting Linnen v. A.H. Robins, Inc., No. 97-2307, (Mass. App.
Ct. 1997)). This wrongful death suit is brought against the manufacturers and
distributors of fen-phen and the doctor who prescribed it, alleging a failure to
warn of the risks involved. Id.
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taken fen-phen which resulted in alleged dangerous side effects
including valvular heart disease. 5 2 Moreover, a Brooklyn woman
filed a ten million dollar lawsuit alleging that fen-phen led to two
surgeries for heart valve replacements.'53 Lastly, a wrongful death
action in Orange County asserts that a doctor prescribed fen-phen
which eventually led to a patient's blocked heart artery and death
in August 1996.154
In January 1997, Wyeth-Ayerst, a manufacturer of fenfluramine,
sent letters to 470,000 medical professionals advising that the
concomitant use of fen-phen is not recommended.' On July 8,
1997, the Mayo Clinic reported a clinical observation of valvular
heart disease in twenty-four patients who had ingested fen-
phen. 156 In light of the Mayo Clinic's findings, Jenny Craig Inc.
said it was recommending that doctors stop prescribing the drug
152 See Gardner v. Gate Pharmaceuticals, No. 97-2542, (N.D. Cal. 1997).
The complaint was filed on July 9, 1997, alleging that the manufacturers failed
to adequately warn that the FDA had not approved the concomitant use of the
drugs. Id.
53 Kathleen Kerr, B'klyn Woman Files $10 million Fen-Phen Suit, N.Y.
NEWSDAY, Aug. 15, 1997, at A33. The complaint alleges that "drug companies
failed to ensure safety for consumers when they tested, manufactured and
marketed fen-phen." Id.
154 Lawsuit Says Faulty Advice on Fen-Phen Led to Death, ORANGE COUNTY
REGISTER METRO, Aug. 15, 1997, at B02. Autopsies by the county coroner's
office revealed that at least seven people died of heart disease in the past year
with fen-phen in their system. Id.
' Valvular Heart Disease in 33 Fen-Phen Patients Spurs FDA "Dear
Doctor" Letter: Agency Will Meet With Manufacturers of Obesity Drugs to
Discuss Labeling Changes, 9 HEALTH NEWS DAILY 131, July 9, 1997, available
in WEsTLAW, Health & Medicine Database, HND File. The letter stated that the
"safety and effectiveness of the use of fenfluramine and phentermine in
combination have not been established." Id.
156 Shelly Plutowski, Valvular Heart Disease Associated With Commonly
Prescribed Diet Pills: Mayo Clinical Observation Raises Questions About
Fenfluramine-Phentermine Therapy (last modified Aug. 29, 1997) <http://www.-
mayo.edu/news/mayo%20ROCHES.. .97/07-Jul-97/fenphen/fen-phennews.html>.
"All 24 patients had cardiovascular symptoms or a heart murmur." Id.
Subsequent testing revealed that heart valves were thickened and blood was
leaking backwards. Id.
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combination of fenfluramine and phentermine. ' That same day,
an FDA Public Health Advisory was issued to remind health care
practitioners that the safety and efficacy of the concomitant use of
fen-phen has not been established. 158 The FDA recommended that
physicians follow their patients closely with periodic and thorough
,57 Diet Centers RethinkPrescribingFen-Phen Combo, STAR TRIB. (St. Paul,
Minn.), July 20, 1997, at 05E. However, Nutri-System continues to promote
herbal fen-phen as a natural alternative to other diet drugs. Id. This product
contains ephedrine, an herbal stimulant, which has been involved in more than
a dozen deaths. Id. The FDA has proposed banning any marketing of such
products. Id.
Over the counter, $23.99 will buy a 15-day supply of "herbal fen-
phen," priced at General Nutrition Centers at Oakwood mall. The
active ingredient- St. John's wort, which works like fenfluramine, and
ma huang, which is also sometimes called ephedra and works like
phentermine- are becoming medically suspect for the same reason as
their prescription counterparts.
Harpster, supra note 118, at Fl. St. John's wort contains the active ingredient
hypericin which is used to treat mild to moderate depression by elevating the
body's level of serotonin. See Barbara Russi Samataro, Herb Found To Suppress
Appetite, Too, CHI. SUN-TIMES, Oct. 15, 1997, at 60. "In the United States, it has
been available in vitamin and health food stores for years but was not widely
known. All that changed [on] June 28- the day the ABC program 20/20 aired a
glowing report on the plant's anti-depressant qualities." Peter Larsen, A More
Natural Prozac? St. Johns Wort Users Want To Get To The Root Of Their
Depression, FORT WORTH STAR-TELEGRAM, Nov. 19, 1997, at 5.
... Lumpkin, supra note 8. The Summary of Reports reads:
As of July 8, 1997, there have been 33 cases reported to [the] FDA of
unusual valvular morphology and regurgitation involving the mitral,
aortic, and/or tricuspid valves, usually being multivalvular. About half
of the women were reported to have pulmonary hypertension with their
valvular disease. All 33 patients were American women with a mean
age of 43.3 years (range: 35-72), all of whom had received combined
fenfluramine and phentermine therapy for between 1 and greater than
16 months (mean 10) before presentation with their valvular disease.
Echocardiographic confirmation of valvular disease was seen in nearly
all of these patients. To date, surgical intervention has been required
in six patients; the histopathology of the diseased valves resembled that
seen in carcinoid syndrome or ergotamine toxicity. The course of the
cardiac valvulopathy in individuals after the drugs are stopped is
presently unknown.
Lumpkin, supra note 8.
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cardiac evaluation.' 59 Also, the findings prompted the FDA to
send out "Dear Doctor" letters warning physicians of the potential
for heart problems. 160
Fen-phen, widely and aggressively advertised as "the medication
that would allow you to eat and live like a 'normal' person,,
161
has proven to be a prime example of the potential danger of off-
label uses of drugs. As of July 21, 1997, ten patients needed open-
heart surgery as a result of taking fen-phen. 162 Some six million
Americans are estimated to have tried fen-phen last year prior to
doctors finding heart valve side effects. 163 By July 22, 1997, an
additional seventeen cases of heart disorder were reported."6
59 Furthermore, "as signs and symptoms of cardiopulmonary disease
develop, further cardiac evaluation should be pursued." Lumpkin, supra note 8.
60 Langreth & Ingersoll, supra note 6, at B 1. In January 1997, American
Home notified doctors that appetite suppressants that were used for more than
three months were linked to a 23-fold increase in the risk of pulmonary
hypertension. Langreth & Ingersoll, supra note 6, at B1. "Proponents of the
drug[s] counter that there is ample evidence that obesity [itself] causes high
blood pressure and heart disease." Langreth & Ingersoll, supra note 6, at B 1.
161 MARKETLETITER, supra note 7. A class action lawsuit was recently filed
against the manufacturers of fenfluramine and phentermine focusing on both
primary pulmonary hypertension and the heart valve abnormalities. MARKETLET-
TER, supra note 7. The suit alleges that the manufacturers and distributors both
knew of and encouraged the off-label use of the drugs. MARKETLETITER, supra
note 7.
162 Fen/Phen Critics Fight Bill That Would Push Unapproved Drugs, Dow
JONES NEWS SERVICE, July 21, 1997, at 18:11:00. The Senate is preparing
legislation called the "killer fen-phen" amendment to allow drug salesmen to
provide doctors with studies promoting unapproved uses of medicines. Id. The
FDA's concerns with the bill include: (1) doctors may not necessarily take the
time out of their busy schedules to read further research to ensure that the
company promoting the drug is adequately portraying all aspects of it; (2) small-
scale studies are ineffective because they do not involve a larger subject pool that
would more adequately represent the likelihood of side effects; and (3) the
company will not have an incentive to do more thorough research. Critics Seize
on Fen-Phen Scare to Fight Senate Drug Legislation, STAR-TRIB. (St. Paul,
Minn.), July 22, 1997, at 07A.
16 See Laura Johannes, Significant Heart- Valve Leaks Found in Large-Scale
Study of Diet Pill Users, WALL ST. J. (Europe), Nov. 13, 1997, at 8.
"6 FDA Finds 17 More Cases Link Fen/Phen, Heart Ails, COMMERCIAL
APPEAL (Memphis, Ten.), July 22, 1997, at A5. The FDA has yet to evaluate the
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Three days later, the diet drug combination was being held
accountable for causing heart and lung problems that led to a Fargo
woman's death. 65
Manufacturers then began working with the FDA to develop
warning language to reflect concerns over the side effects associ-
ated with fen-phen. 66 The revised labeling would include a
boxed warning about a possible heart valve disorder associated with
the drug's use,167 although doctors still do not know how fen-
phen causes heart valve injuries. 168 For Vicki Thomas, the warn-
ings were too little too late. 169 At age 41, Ms. Thomas was
diagnosed with primary pulmonary hypertension and the condition
has only worsened. 7 ' She is in desperate need of a heart-lung
transplant, has weakened kidneys, and claims that "the only things
reports and establish a direct link between the consumption of fen-phen and heart
valve problems. Id. However, Dr. Mehmood Khan, chief of endocrinology at
Hennepin County Medical Center in Minneapolis, studied 307 echocardiograms
and found a "[c]lear association between [diet] drug therapy and heart-valve
problems." Johannes, supra note 163, at 8.
165 Hospital: Fen-Phen Didn 't Cause Fargo Death, STAR-TRIB. (St. Paul,
Minn.), July 25, 1997, at 03B. The autopsy showed that the patient suffered from
pulmonary hypertension. Id. However, the hospital claims this condition did not
contribute to her death. Id.
166 Wyeth-Ayerst to Add Information to Labeling of Antiobesity Therapies,
PR NEWSWiRE, July 25, 1997, at 14:14:00.
167 Id. The boxed warning is a method used to prominently display
information of a critical nature. Id. The warning will also contain language
regarding the risk of primary pulmonary hypertension. Id. However, doctors also
note that the link between the treatment of obesity with fen-phen and valvular
heart disease is inconclusive. Id.
168 BLOOD WEEKLY, supra note 145. Dr. Heide Connolly, Mayo cardiologist,
stated: "We believe that these cases raise significant concern that this combina-
tion of appetite suppressants can have important implications regarding valvular
heart disease, but more comprehensive stud[ies], which we are planning, [are]
needed to make a definitive statement about the association." BLOOD WEEKLY,
supra note 145.
169 Anne Marie O'Neill & Michele Keller, Bitter Pills: Vicki Thomas Lost
Far More Than Pounds on the Diet Drugs Fen-Phen, PEOPLE, Aug. 18, 1997,
at 105. Vicki Thomas was 5 feet, 6-1/2 inches and 157 pounds and wanted to
lose 15 pounds. Id.
170 Id.
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that don't hurt are the tip of my nose and my eyeballs. It has been
hell. ,,0
71
Primary pulmonary hypertension is "increased blood pressure
in the blood vessels of the lungs.' 72 Fen-phen has been linked to
this condition due to ties to the increased level of serotonin in the
synaptic clefts which occurs after ingesting fen-phen. 173 This in-
creased level of serotonin constricts the veins, raising the blood
pressure and resulting in a restriction of blood flow.17' Heart
valve damage is evidenced by a "glistening white or wax appear-
ance" on the leaflets and chords of the valve and induces symptoms
including shortness of breath, fatigue and extreme swelling in the
lower extremities. 175 Additionally, switching to natural forms of
fen-phen may not be a safer alternative because herbal fen-phen,
diet-phen and fen-chi contain ephedra which has been implicated
in more than 800 reports of adverse events, among them twenty to
thirty deaths.176 Nevertheless, neighborhood drug stores will stock
171 Id. While it is not possible to prove that the drugs caused her condition,
her cardiologist, Dr. Bruce Brundage, thinks that no physician should advocate
fen-phen for people who want to lose a few pounds. Id.
172 Rheingold, supra note 133, at 22. The term "primary" implies no known
cause. Rheingold, supra note 133, at 22.
173 Rheingold, supra note 133, at 22.
17" Rheingold, supra note 133, at 22 (citing <http://www.netmedicine.com/pt-
/PTINFO/Prim-ph.html>). A world-wide group known as the International
Pulmonary Primary Hypertension Study "found a 23 times increase of PPH in
those who used fen-phen for more than three months over non-users." Rheingold,
supra note 133, at 22.
175 Rheingold, supra note 133, at 22. Patients developing these symptoms or
a new heart murmur throughout the course of therapy should consult a physician
and request a complete cardiac evaluation. See Charles W. Henderson,
Information Added to Anti-Obesity Therapy Labeling, DISEASE WEEKLY PLUS,
Aug. 11, 1997, available in 1997 WL 11421558.
176 Lisa Jennings, It's Still A Drug: 'Natural' Forms of Fen/Phen Can
Produce Damaging Side Effects, COMMERCIAL APPEAL (Memphis, Ten.), Aug.
3, 1997, at Fl. Reports ranged from unpleasant side effects to more serious ones
including seizures, heart attacks and strokes. Id. Under the Dietary Supplement
Health and Education Act of 1994, dietary supplements are not required to be
tested for safety and efficacy prior to shelving. Id. However, a current FDA
proposal seeks to limit Ephedrine alkaloids in dietary supplements to no greater
than eight milligrams per serving. Id. It could be almost two years before the
833
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their shelves with herbal fen-phen simply due to high consumer
demand.177
Unfortunately, no animal studies or good clinical testing has
been done on the effects or adverse reactions of fen-phen.'78 It is
therefore no wonder that the controversy surrounding the drugs' use
continues. As recently as August 20, 1997, doctors asserted that the
drugs do not increase serotonin levels in the blood that reaches the
heart, but reduces such levels. 179 The National Institute of Mental
Health ("NIMH") discovered that the drug works similarly to
Prozac by enhancing pleasant emotions while diminishing unpleas-
ant ones. 8' It has been asserted that the problem arises with the
proposed regulation becomes final. Carolyn Poirot, Herbal Fen-Phen Sales Are
Up- As Are Warnings Flags, FT. WORTH STAR-TELEGRAM, Aug. 21, 1997, at 1.
See also US. HHS: FDA Warns Against Drug Promotion of "Herbal Fen-Phen '"
M2 PRESSwIRE, Nov. 7, 1997, available in 1997 WL 15142782. The agency is
warning consumers that the herbal form of the drug has not been proved safe and
effective for human consumption. Id. "The FDA warned that companies are
violating federal law by advertising the dietary supplements as weight-loss
products-or implying such a benefit by mimicking the prescription drug names
[.. t]he average consumer would look at this product and think, 'Wow, this is
the same name as fen-phen, it must provide the same benefit."' Government
Cracks Down on Diet Supplement "Herbal Fen-Phen, " SAN DIEGO UNION-TRIB.,
Nov. 7, 1997, at A9.
177 Jennings, supra note 176, at Fl (noting that "[h]erbal fen-phen is the
lesser of two evils").
17' Rheingold, supra note 133, at 22. Hence, the prescribing physician and
the patient have none of the scientific support which the FDA requires before a
drug is marketed. Rheingold, supra note 133, at 22.
179 Dieter's Valve Damage Needs More Research, WALL ST. J., Aug. 20,
1997, at A 15. It is argued that fenfluramine blocks the reuptake of serotonin into
platelets, leaving them to be destructed by monamine oxidase (MAO). See
JULIEN, supra note 134, at 495 (noting that MAO is an "[e]nzyme capable of
metabolizing norepinephrine, dopamine, and serotonin to inactive products").
However, it is still possible to have increased serotonin levels in brain synapses.
Dieter's Valve Damage Needs More Research, supra, at A15.
IS' Risk in a Pill Society: Some New Prescription Drugs Are Only Dimly
Understood By Science, L.A. TIMES, Sept. 1, 1997, at B4. The method by which
serotonin works remains a mystery among many individuals in the medical
profession. Id. For example, William S. Appleton, a Harvard Medical School
psychiatrist, stated: "I have begun to regard the serotonin synapse the same way
I think of my radio when it does not work-I hit it and it often starts broadcast-
834
FEN-PHEN
fen-phen cocktail because it not only prevents absorption of
serotonin, but also decreases the brain's sensitivity to that neuro-
transmitter. 8' In other words, it is still under investigation to
discover the exact mechanism of action for serotonin and its
fluctuating effect on fen-phen users. Not surprisingly, a citizen's
petition dated around August 21, 1997 requested the FDA to
rescind approval of the drugs because of the "imminent danger to
the public safety." 182
Concerns about the apparent direct causal relationship between
ingesting fen-phen and cardiac and respiratory malfunctioning
climaxed as a result of the New England Journal of Medicine's
publication demanding a moratorium on the use of anorectic drugs
for cosmetic purposes. 183 Results of the study indicated that the
use of anorectic drugs caused pulmonary hypertension. 84 The
affected mitral, aortic and tricuspid heart valves resulted in valve-
replacement surgery for five patients. 85 Through examinations,
researchers concluded that appetite-suppressant drugs cannot
ing again. I have begun to believe that is what these antidepressants do to the
synapse-they hit it." Id.
'81 Id. Given the vast quantity of individuals now taking the drugs, the
NIMH study should remind us to fight our natural instinct to believe in the
curative powers of medicine to the extent that we lose sight of the various
complications that accompany the pharmacological products.
182 HEALTH NEWS DAILY, supra note 30. The petition was filed with the
FDA by Ronald Benjamin, a Binghamton, New York attorney, on behalf of two
patients claiming to have experienced cardiovascular-relatedside effects from the
anti-obesity drugs. HEALTH NEWS DAILY, supra note 30.
183 Gregory D. Curfrnan, Diet Pills Redux, 337 NEw ENG. J. MED. 629, 629-
630 (1997). The method by which these drugs cause pulmonary hypertension has
not been established conclusively, particularly because it has been impossible to
reproduce the disease in animals. Id.
184 id.
185 Id. It is speculated that serotonin was involved with the injuries to the
heart valves. Id. Because of the severity of the effects, the editors of the New
England Journal of Medicine released the finding of the paper "more than seven
weeks before publication." Id. "The editors believed that doctors and their
patients needed to be alerted quickly, so that appropriate decisions could be made
and the scope of the problem could be rapidly assessed." Id.
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maintain weight loss indefinitely.186 Furthermore, a recent study
has found that a dose comparable to that prescribed to reduce
weight in humans caused neurotoxicity in monkeys which can
result in mood, memory and sleep problems.1 87 However, as with
every controversial issue, some users continue to advocate the
drug's effectiveness. They say exactly what dieters want to hear,
and believers hear only these messages of hope and herald these
words as the truth in the face of compelling evidence to the
contrary.
D. Addressing The Problems Of Fen-Phen
Even the believers of fen-phen have to start losing hope. It
appears that the perils of weight loss pills far outweigh the benefits
that are cited few and far between. The big news is that fen-phen
does not result in significant weight loss because the average
weight loss is approximately five and one-half pounds more than
dieting alone. 188 Such a finding begs the question, is the diet-pill
craze coming to a close? While "America has clearly not lost its
appetite for drugs,"'89 sales of diet pills are diminishing rap-
186 Id. To date, efficacy only for short-term weight loss has been proven
conclusively. Id. Safety becomes more doubtful when taking the drug over an
extended period of time because the risk of serious toxicity increases with use.
Id.
187 U.S. HHS: Psychiatric Symptoms May Signal Brain Damage From Diet
Pills, M2 PRESSWIRE, Aug. 27, 1997, available in 1997 WL 13653387. This
study suggests that fen-phen use may result in irreversible loss of brain serotonin
nerve terminals. Id. In this study, the monkeys' brains continued to show signs
of damage seventeen months after taking fen-phen. Id. However, there is no
evidence that such harmful changes would occur in humans. Id.
188 Jane E. Brody, Hard Evidence Building Against Fen-Phen Safety,
PORTLAND OREGONIAN, Sept. 3, 1997, at E12. Also, dieters regain some or all
of the weight when they cease taking the drugs. Id. Proponents of fen-phen assert
that "although the drugs sometimes might be hazardous, obesity itself is a far
greater risk." Id. Excess weight "results in 300,000 deaths a year from causes
such as heart disease, diabetes, kidney disease, and stroke." Id.
189 Andrew K. Skolnick, Lessons From US. History of Drug Use, 277
JAMA 1919, 1919 (1997). Skolnick notes the irony that while America is
passing strict regulations concerning the tobacco industry and no longer
sympathizing with the problem drinker, "we are [at the same time] taking Prozac
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idly.'90 Furthermore, the National Association to Advance Fat
Acceptance and the Council on Size and Weight Discrimination
recently filed suit in United States District Court in Washington
seeking to compel the government and drug companies to remove
fen-phen and redux from the market. 191
On September 15, 1997, fenfluramine was removed from the
market after new evidence linked its use to serious heart valve
problems.'92 After analyzing heart tests on 291 fen-phen users
and noting that ninety-two had damaged heart valves, the FDA was
forced to take prompt action. 93 The FDA concluded that fenflura-
in record numbers [and] slimming down with Fen-Phen." Id.
90 Laura Johannes & Steve Stecklow, Trimming the Sales: Diet-Pill
Prescriptions Plummet as Concerns Rise Over Side Effects, WALL ST. J., Sept.
4, 1997, at Al. According to David Crossen, an analyst of Montgomery
Securities in San Francisco, Redux "was the fastest launch of a drug ever. In the
first 11 weeks it hit an annual sales rate of $220 million." Id. Mr. Crossen sees
current annual sales closer to $70 million. Id.
.9 Advocates For Fat PeopleSue Over Weight-Loss Drugs, ST. LOUIS POST,
Sept. 6, 1997, at 21. The suit asks for a fund to be established to offset the harm
that resulted from the promotional activities that made fen-phen a household
term. Id. Sally Smith, a member of the Fat Acceptance Group, said that the
organization "feels strongly that what's at stake in this lawsuit is the health and
well-being of Americans all sizes of large. The FDA has been asleep at the
wheel, and drug manufacturers are profiting from the desperation of fat people."
Id.
192 Marlene Cimons, 2 Diet Drugs Tied to Heart Problems Taken Off the
Market: Action Effectively Ends Fen-Phen Combination, L.A. TIMES, Sept. 16,
1997, at Al. "Despite the continued availability of phentermine, experts do not
expect it to be combined with" other drugs given the problems in the present
situation. Id. But see Johannes & Stecklow, supra note 190, at Al (noting that
Nutri/System is now recommending that clients switch to phen-pro, a combina-
tion of Phentermine and Prozac, absent any studies for its safety and efficacy).
Phen-pro works differently than fen-phen, but it still suppresses appetite.
Johannes & Stecklow, supra note 190, at Al. There is no evidence that the
concomitant use of the drugs enhances either drugs' effect. Johannes & Stecklow,
supra note 190, at A 1. "Although phentermine... was not recalled, it does have
the potential to cause some side effects. They include rapid heart rate, insomnia,
anxiety, headache, dry mouth, digestive upset, changes in libido and increases in
blood pressure." Joe Graedon & Teresa Graedon, Ph.D., Legal Issues May Make
Doctors Leery of Fen-Phen, BALTIMORE SUN, Nov. 11, 1997, at 5E.
1' Cinons, supra note 192, at Al. Yet this decision does have its critics. Dr.
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mine presented an unacceptable risk of heart problems to pat-
ients."' At this point in time, due to the recall of fen-phen, the
biggest problems appear to be the long-term repercussions for post
users and determining what steps can be taken to reduce adverse
effects.'9
Approximately one hundred lawsuits have been filed around the
country alleging heart-valve problems, primary pulmonary
hypertension and brain damage as a result of ingesting fen-
phen.196 Yet the dilemma for the FDA remains virtually un-
Bernard Ginsberg, a Santa Monica physician with an extensive weight-loss
practice, asserts that he "would have preferred an alert to doctors, rather than
taking the drugs off the market." Cimons, supra note 192, at Al. Dr. Ginsberg
continued, "[Patients] didn't know when it was time to eat unless they were told;
and when they ate something, they got full right away. I thought it was a
panacea, but sometimes some things are too good to be true." Cimons, supra note
192, at Al.
' John Schwartz, 2 Diet Drugs Are Pulled Off Market: Health Concerns
Grow After FDA Links Pills to Rare Heart Problem, WASH. POST, Sept. 16,
1997, at A01. At least three deaths had been linked to the use of the drug to
date. Id. "The FDA said the valve problems can cause a backflow into a heart
chamber, increasing the risk of bacterial endocarditis, a potentially fatal infection
of the heart's lining, during invasive medical and dental surgery." FDA Says
Fen-Phen Users Need Doctor's Examination, WALL ST. J., Nov. 14, 1997, at
B 13. The FDA issued the recall after learning that almost one-third of patients
studied evinced heart-valve damage. See Keep the Watchdog Well-fed: Action
Against Fen-Phen Shows the Need For a Vigorous FDA, L.A. TIMES, Sept. 18,
1997, at B8.
195 See John G. Auerbach, What the Diet-Drug Recall Means to Patients,
WALL ST. J., Sept. 16, 1997, at B1. "Physicians, of all people, might be expected
to be skeptical and respect the powerful effects of drugs.... You'd think they
would wonder at the very least if what they are doing is safe. How do they know
they are doing no harm." See Gina Kolata, How Fen-Phen, a Diet 'Miracle,'
Rose and Fell, N.Y. TIMES, Sept. 23, 1997, at Fl.
196 See Laura Johannes & Richard Schmitt, Lawyers Prepare for Deluge of
Diet-Drug Suits, WALL ST. J., Sept. 17, 1997, at B1. Rarely do drug companies
confront such a large group of people affected in such a disastrous way. Id. Even
newspapers are advertising lawyers groups selling memberships to new diet-drug
litigation for $250. Id. Desire to become involved in this litigation is readily
apparent: analysts estimate that liability could exceed $4 billion. Id. Furthermore,
some lawyers are contemplating filing suit against the manufacturers under the
Federal Tort Claims Act. Id. Class-action suits were filed in New York, Utah,
Colorado, California, and Hawaii arguing that "[t]housands of people will now
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changed: "It must address public, political and industry pressure to
approve promising new drugs quickly and yet protect Americans
from unsafe medications."'97 It is clear, after the fen-phen fiasco,
that the FDA needs a stricter procedure for the evaluation of new
drug uses. However, logic runs amiss as seen by a recent bill which
was proposed to Congress that would shorten the approval process
by requiring only one clinical trial to prove safety and efficacy.19
Supervision, as a whole, is virtually absent.'99
need regular medical attention for which the drug makers must be held
responsible." See Lawsuits Filed Against Makers of Fen-Phen, WASH. POST,
Sept. 22, 1997, at All. Moreover, a suit, believed to be the first in Orange
County dealing with the effects of fen-phen, was filed recently. See Marcida
Dodson, 0. C. Clinic Named in Fen-Phen Lawsuit, L.A. TIMES, Sept. 30, 1997,
at A22. This class-action suit was filed by a woman alleging heart problems as
a result of taking the drug combination. Id. Also, a Punta Gorda woman filed a
federal class action suit against eight drug companies alleging the drug
combination damaged her heart and lungs. Id. The suit claims that fen-phen
"represents an imminent public health danger." See Stephen Nohlgren, Class-
action Lawsuit Challenges Safety of Fen-Phen, ST. PETERSBURG TIMES, Oct. 1,
1997, at lB. Additionally, a North Carolina law firm filed a class-action suit
against five drug companies in hopes of receiving $75,000 for each plaintiff to
cover continual medical services. See Catherine Clabby, Class-action Suit Takes
Aim at Popular Diet Medications, NEWS & OBSERVER (Raleigh, N.C.), Oct. 2,
1997, at A3.
197 Laura Johannes & Steve Stecklow, Withdrawal of Diet Drug Raises
Questions in US., WALL ST. J. (Asia), Sept. 17, 1997, at J6. The FDA and drug
companies continue to assert that they took swift action to protect the public,
despite the lack of conclusive proof that the drug combination is directly
responsible for the reported adverse effects. Id.
"g Danger Off the Label, NEWS & OBSERVER (Raleigh, N.C.), Sept. 22,
1997, at A10. The post-approval regulation, or lack thereof, with off-label uses
of drugs appears to pose the greatest risk to the public. Id. The bill before
Congress, HR 1710, does not address this issue. Id. Moreover, it would permit
manufacturers to promote off-label uses. Id. The only monitoring by the FDA is
on a voluntary basis. Id. The author argues "either give the agency enough
resources to monitor drugs' use and effects thoroughly ... or create an
independent agency analogous to the National Transportation Safety Board to
keep an eye on prescription drugs." Id.
'99 Kolata, supra note 195, at Fl. "The tale speaks to the limitations of
current methods of evaluating drug safety. It speaks to the willingness of some
doctors, who see a quick flow of ready cash free from the constraints of managed
care, to lure desperate patients, who will do almost anything to lose weight."
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On September 24, 1997, the Senate approved legislation that
effectively made FDA approval of new drugs an easier and faster
process. °° Consumer groups reacted to this new legislation by
saying, "the senators who voted for this bill voted for more drug
disasters like fen-phen. ' '20 1 Others responded, "[t]he world some-
times can't appreciate a new idea. 20 2 It is difficult to accept this
new legislation when as recently as October 4, 1997, the FDA
Kolata, supra note 195, at Fl. The result of the off-label prescription practice is
"fen-phen mills." Kolata, supra note 195, at F1. The solution may be to require
long-term follow-up studies so that serious side effects could be brought to light.
Kolata, supra note 195, at Fl. The process, as it now stands, allows doctors to
practice witchcraft. Kolata, supra note 195, at Fl.
200 See Helen Dewar & John Schwartz, Senate Votes to SpeedFDA Approval
Process for Drugs; Medical Devices, WASH. POST, Sept. 25, 1997, at A15. The
bill was approved by a vote of 98 to 2. Id. The two members opposing the bill,
Senators Edward M. Kennedy (D-Mass.) and Jack Reed (D-R.I.) voiced their
concerns regarding endangering consumers by false labeling products. Id. The
bill, inter alia, (1) requires the FDA to speed approval of new drugs and devices
aimed at treating serious illnesses for which there is no therapeutic cure; (2)
allows the FDA more discretion over the number of clinical trials that drug
companies conduct to test the effectiveness of the drug, which would make it
easier to gain drug approval after a single trial; and (3) provides companies with
a greater ability to supply doctors with information regarding off-label uses for
prescription drugs. Id. Companies must commit to further research and agree to
seek FDA approval when promoting new and expanded uses. See Marilyn Chase,
FDA Reform May Open A Door to Abuses In Drug Promotions, WALL ST. J.,
Sept. 29, 1997, at B1. Therefore, it is not necessarily "[t]urning regulatory red
tape into green lights for new drugs." Id.
201 Dewar & Schwartz, supra note 200, at A 15. Yet advocates contend that
the approval of the bill is one of the most important steps forward in recent
years. Dewar & Schwartz, supra note 200, at A15. Others note that the pressure
for approval was substantial because the Prescription Drug User Fee Act, which
allows for the prescription drug industry to underwrite the cost of reviews of
drugs and enables the FDA to reduce its review time for drugs, was up for
renewal. Dewar & Schwartz, supra note 200, at A15.
202 Michael James & Dail Willis, "Father of Fen-Phen "Brushes Off Office
Raid; Timonium Doctor Will Still Prescribe Drug, BALTIMORE SUN, Oct. 2,
1997, at IA. Dr. Pietr Hitzig, who prescribes fen-phen (from accrued supplies)
to treat obesity, claims that he is providing quality health care. Id. However,
investigators have seized his records and argue that his practice of prescribing
fen-phen over the internet may violate a federal statute which requires that
prescriptions be written "in the usual course of professional treatment." Id.
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confirmed that a woman who was taking fen-phen during her
pregnancy caused heart damage to her newborn son.2 °3 It is rather
ironic that President Clinton's Administration continues to assert
that, "the final bill represents a significant step toward accomplish-
ing the mutual goal of assuring the agency's optimum performance
while protecting the health of the U.S. people.
2 4
When given the opportunity, people will seek help for their
over-weight condition and find the answer they are looking for in
a product on the market. °5 The FDA had many options to choose
from to effectively address the adverse side effects attributed to
2013 Sallie Han & Whitney Walker, Fen-Phen & Birth Defects, N.Y. DAILY
NEWS, Oct. 4, 1997, at 3. A $67 million lawsuit was filed in Manhattan by a
woman claiming that her son was born with a heart defect due to his exposure
to fen-phen in the womb. Id. Her baby was born with "blue baby syndrome"
(lacking a pulmonary artery) forcing him to undergo open-heart surgery. Id. For
more information on the effects of fen-phen, pregnant women are invited to call
the California Teratogen Information Service at the University of California, San
Diego/UCSD Medical Center at (619) 543-2070. See Diet Pills'Prenatal Effects
Studied, PRESS ENTERPRISE (Riverside, Cal.), Oct. 14, 1997, at CO.
204 Progress on U.S. Senate and House FDA Reform Bills, MARKETLETrER,
Oct. 6, 1997, available in 1997 WL 14509968. It becomes increasingly apparent
that the Senate values industry profits over public health. Id. The House of
Representatives and Senate have each passed different bills which attempt to
streamline the FDA. See Undermining the FDA Series: Editorials, ST.
PETERSBURG TIMES, Oct. 14, 1997, at 1OA. The House version of the bill would
allow companies to promote off-label uses of the drugs that they manufacture.
Id. The Senate version restricts the government's ability to protect patients from
certain medical devices. Id. "Under the compromise, drug companies will be able
to circulate medical journal articles on unapproved uses of drugs, but only after
obtaining FDA clearance. In addition, the companies will be required to study
the safety of specific off-label uses and seek FDA approval for them within three
years." See Bruce Ingersoll, Congress Clears Bipartisan Bill To Speed FDA
Review of New Drugs and Devices, WALL ST. J., Nov. 10, 1997, at B12.
205 Sandy Banks, The Dire Consequences of Pursuing Beauty, NEWS &
OBSERVER (Raleigh, N.C.), Oct. 2, 1997, at E4. "Forget the health risks and get
out of our way; we're chasing a dream ... magic pills with the power to melt
away pounds without making you hungry or grumpy or sick." Id. Fen-phen has
become the tragedy of the times. Id. Our society is, without a doubt, weight-
obsessed. Id. "[W]e've bet on Jenny Craig and Nutri-System, Slim Fast and
Dexatrim, Weight Watchers and Overeaters Anonymous. And in the absence of
fen-phen, we'll continue to search for that magic bullet." Id.
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fen-phen use. The agency could have labeled the drugs and limited
the dispensing of the drugs in such a way as to prohibit their use
in combination or could have limited the dispensing of the drugs
to the "morbidly obese. '20 6 Instead, the FDA approved each drug
and blindly allowed their combined use.20 7 Granted, FDA approv-
al of a drug does not mean that the user is ensured safety and
protected from all possible resulting harm.2 8 However, such
approval provides some comfort to the user in knowing that the
drug has passed numerous animal and clinical studies. Thereafter,
the consumer can make a more informed and educated decision
regarding use.20 9
Pick your poison as the cycle continues: if it's not one drug, it's
another. All of them promise to make one's dream a reality, yet
one must realize that the answer to trimming down is not found in
a bottle. Despite the widespread use of pharmacologic therapies, the
206 Henry I. Miller, Fen-Phen Flap No Cause For New Regulatory Fat,
WALL ST. J., Sept. 23, 1997, available in 1997 WL-WSJ 14167245. Morbid
obesity is defined as "when the patient is more than double his ideal weight and
subject to life-threatening complications." Id. The FDA might also have required
a boxed-warning to patients using either fenfluramine or phentermine. Id.
207 Phen-Fen Dreams, BANGOR DAILY NEWS, Sept. 24, 1997, available in
1997 WL 11882815. "[S]o many people blithely gave over their bodies to these
serious drugs with the idea of dropping a few pounds." Id.
208 Shute, supra note 9, at 7475. Since 1980, 13 drugs have been recalled
because they have proven to be unsafe. Shute, supra note 9, at 7475. Addition-
ally, an estimated 51% of FDA-approved drugs have major adverse effects that
are not detected until used by the general public. Shute, supra note 9, at 7475.
Nearly 140,000 people each year die from an adverse reaction to prescription
drug use. Shute, supra note 9, at 7475. For example, Roche Holding Ltd.
withdrew its application from the FDA after noting a link between Xenical and
precancerous lesions of the breast. See Robert Langreth, Roche Seeks US.
Approval For Xenical, WALL ST. J. (Europe), Nov. 17, 1997, at 3. If it had been
approved, Xenical would have been the first "fat-blocker" drug in the United
States. See Lawrence G. Proulx, Diet Drugs At A Glance, WASH. POST, Nov. 18,
1997, at Z07.
209 Kathleen Kerr, Fen-Phen Records: FDA Knew Of Risks-Reports Were
Filed On Adverse Reaction, SUN-SENTINAL, (Ft. Lauderdale, Fla.), Oct. 20, 1997,
at 3A. Frighteningly enough, fen-phen was labeled as a suspect medication "in
at least 70 deaths reported to the FDA between 1974 and 1997, but those reports
were never disclosed" to the public. Id.
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prevalence of obesity continues to increase, and the results of
treatment remain unsatisfactory.210 In general, maintaining a
reduced weight requires exercise and a diet, not necessarily medical
supervision or drugs. "Hopefully, doctors, Congress and weight-
obsessed Americans will learn [fen-phen's] powerful lesson: There
is no magic potion." ''1 In an effort to protect the public, the FDA
must take an affirmative step to regulate off-label dispensing of
drugs.
IV A PROPOSAL To INCORPORATE OFF-LABEL USES OF DRUGS
UNDER FDA REGULATION
The standard for safety and efficacy requires experts to evaluate
scientific data in an effort to ascertain if the potential benefits of a
new drug outweigh the potential harms.12 It becomes increas-
ingly apparent that restricting a company's ability to disseminate
information about off-label uses of drugs does nothing more than
invite other means to achieve the same end. All it really takes is
one crafty salesperson to find a loophole in what it means to
"distribute" information, and the cycle starts again.
21' Long-term Pharmacotherapy in the Management of Obesity: National
Task Force on the Prevention and Treatment of Obesity, 276 JAMA 1907,
1907-15 (1996).
21 The Cult of Thinness, ST. Louis POST-DISPATCH, Sept. 20, 1997, at 30.
Although intended only for the obese, weight-loss programs and diet gurus
showcased the drug. Id. Yet, upon the Mayo Clinic's findings, the drugs were
recalled. 1d. The disastrous effects should be a warning to the Senate that drug
companies should be required to market drugs [via FDA approval] which are to
be used for off-label purposes. Id. The practice has proven far too dangerous to
allow drug companies and doctors to effectuate inappropriate prescriptions
without empirical evidence to reveal potential negative consequences. Id.
212 See DIXON & WOODSIDE, supra note 14, at 8-7. Drug product litigation
involving determinations of safety and effectiveness can reasonably be said to be
a forum for evaluating methodologies which will have a profound effect, good
or bad, upon the health of citizens. See 21 U.S.C. §355(d) (1962) ("If the
Secretary finds . .. the reports do not include adequate tests by all methods
reasonably applicable to show whether or not such drug is safe for use under the
conditions prescribed, recommended, or suggested in the proposed labeling
thereof, he shall issue an order refusing to approve the application.").
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The power to distribute off-label drugs effectively makes human
beings guinea pigs. While it is somewhat pedantic, it must be
reiterated over and over again: physicians are dealing with life and
death. Eager consumers are dealing with doctors who are creating
miracle drugs without the slightest inkling of any clinical studies to
support their hunch. These consumers are hoping that this time will
be different, but should we not wonder if there will be a next time?
Society relies on the power of medicine and believes in the "magic
pills," but our trust is being betrayed by our willingness to abide by
a doctor's commands. The stakes are high and the pot is surely not
sweet enough to risk life. The need for new regulation becomes
increasingly apparent when consumers are offered drug combina-
tions that could ultimately cause them irreparable harm.
A. An Off-Label Use Of A Drug Should Be Regarded As A
New Drug That Falls Under FDA Regulation
While it is impossible to guarantee either the safety or efficacy
of a given drug, a new drug may not be marketed or administered
to human beings without FDA approval. 13 A drug may be
regarded as "new" if:
(1) it contains a new chemical substance for medical use;
(2) it is an established drug offered in new dosage form;
(3) it is an established drug offered with new medical
claims; (4) it is an established drug offered at new dosage
levels; and (5) it is an established drug packed in new or
novel packaging materials. 214
The combination of two distinct drugs logically falls under the
"new drug" label which requires additional testing on the new
pharmacologic compound.
213 See Id. § 355(a).
214 DIXON & WOODSIDE, supra note 14, at 8-16; See 21 U.S.C. § 321(p)
(1994) (stating that in particular, if either the composition of a drug product is
not generally recognized as safe and effective among experts qualified by
experience and training to deem the item such or a composition is used under
such circumstances and according to such conditions that the approval is no
longer for that drug product then the combination of two distinct drugs can no
longer be regarded as safe and effective without clinical investigations).
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It is counter-intuitive to allow doctors to combine potent
medications without prior investigations having established that the
new product is fit for human consumption. Just as a product must
meet U.C.C. guidelines for merchantability," 5 prescription drugs
must rise to that standard, if not a higher one, in an effort to
protect society from the unknown. Moreover, if a doctor purports
to know of a particular purpose for which the goods are required
and there is reliance on his or her skill and judgment, there is an
implied warranty that the goods shall be fit for such purposes.2 6
Therefore, the FDA must regulate a doctor's unfettered power to
dispense any number of combinations of pills on nothing more than
a premonition. If a seller's skill or judgment can be held account-
able when the buyer relies on such in accepting goods which later
proved ineffective for the specific purpose they were purchased for,
should not a doctor be held liable for his or her indiscriminate
dispensing of medications when reassuring patients of their
effectiveness?
It is common sense that while two distinct entities may
separately be legal and pose no substantial danger to anyone, the
combination of these two seemingly benign entities can prove
deadly. An example for clarification is drinking and driving. Both
activities are legal if you are of a certain age and, for the latter,
pass state-mandated tests. When combined, the results are disas-
21' While the dispensing of prescription drugs does not involve a seller or
merchant, the analogy is still applicable. For example, U.C.C. § 2-314 provides
that
[g]oods to be merchantable must be at least such as (a) pass without
objection in the trade under the contract description; and (b) in the case
of fungible goods, are of fair average quality within the description;
and (c) are fit for the ordinary purposes for which such goods are used;
and (d) ... [be] of even kind, quality and quantity; and (e) are
adequately contained, packaged, and labeled as the agreement may
require; and (f) conform to the promise or affirmations of fact made
on the container or label if any.
U.C.C. § 2-314 (1977).
26 See Id. § 2-315. The Implied Warranty Of Fitness for a Particular
Purpose, while pertaining to sales of goods, appears to be equally applicable to
off-label uses of drugs.
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trous. Such an outcome is equally applicable to off-label uses of
drugs.
217
The policies discussed earlier in this Note support drastic
limitations on the dispensing of drugs for unapproved purposes. A
proposal for stricter regulation of off-label uses of drugs would
read as follows:
(1) The manufacturers of a pharmacologic drug licensed by the
FDA for sale by prescription shall not be subject to liability for
harm caused by the dispensing of drugs for off-label uses.
(2) Any two drug products, previously FDA approved as
separate pharmaceutical agents, that are being dispensed for
concomitant use shall be termed a "new drug."
(3) New drug status will imply the absence of familiarity with
the chemical and the expert's inability to assess the safety and
effectiveness of the product absent extensive scientific evaluations.
(4) The NDA will specify in bold letters that THE COMBINATION
OF THE DRUGS FOR CONCOMITANT USE IS NOT APPROVED FOR THE
NEW INDICATION.
(5) Any and all combinations of pre-approved drug substances,
where that combination has not become generally recognized as
safe, are "new drugs." Generally recognized as safe will be defined
as: having been exposed to both animal testing and clinical
investigations which result in a compilation of studies indicating all
effects noted with the drug, either causally or peripherally
related."'
(6) New drugs, including new uses for old drugs, must be
approved by the FDA through the aforementioned NDA process
and regarded as safe and effective for its desired use.
(7) Similar to the requirements under 21 C.F.R. § 314.50, a
NDA for a new chemical entity will contain an application, a
summary, a technical section, patient data and case reports, drug
samples and proposed language for labeling.
217 See supra notes 126-209 and accompanying text (discussing the effects
and policies underlying fen-phen dispensation).
2"8 See generally 21 C.F.R. § 310.303(a) (1974).
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(a) The application will contain the name and address of the
applicant along with the drug product's name and proposed
indications for use via prescription.
(b) The summary will contain a general synopsis of the data
and information regarding the empirical findings of studies
conducted on the new drug. To the extent possible, tabular and
graphic forms are advantageous in gaining a more thorough
understanding of the drug's action. The summary shall also include
a thorough explanation of the marketing history of all drug
products involved including reasons for removal for any reason
relating to safety and efficacy. The summary shall conclude with
two sections: (i) the potential clinical benefits of the drug product
and (ii) the potential side effects of the drug product.
(c) The technical section will contain all of the data and
empirical information in sufficient detail in order "to permit the
agency to make a knowledgeable judgment about whether to
approve the application."2 9 This includes: the composition and
specification of the new drug; a full description of the drug
substance including its chemical make-up; a description of the
manufacturing and packaging procedures; assessment of environ-
mental impact; and a section describing the results of animal and
in vitro studies with the drug.
(d) The patient component will contain the findings and
analysis relating to the clinical pharmacology of the drug. In
particular, each study will be addressed separately with an abstract,
introduction, methods, results and discussion section. Each separate
report will conclude with a section addressing the possible
imperfections of the study (i.e. too small of a subject pool, no
placebo effect, too many confounding variables, etc.). The entire
section will conclude with a report entitled "Evidence That
Establishes The Safety and Efficacy Of The New Drug and Noted
Adverse Reactions That Accompany The Drug's Use."
(e) The applicant shall submit a sample of the drug product
proposed for marketing and the drug substance components that
comprise the final product.
219 21 C.F.R. § 314.50(d) (1985).
847
JOURNAL OF LAW AND POLICY
(f) The proposed label shall contain the proposed regulatory
specifications for the drug, directions for use and all side effects
(both confirmed or even remotely related to the drug's use).
(8) The NDA will include all phases of animal and clinical
testing, pre and post-marketing requirements and periodic reports
noting adverse reactions.
(9) The doctor must submit credible evidence, based on robust
data and extensive scientific inquiry, that the proposed off-label
use, if approved, will benefit society for its intended purpose.
Cosmetic enhancement is not an acceptable reason to seek a NDA.
(10) Absent a life-threatening situation, a prescription for the drug
shall be conditioned upon: (1) approval of the NDA by the FDA
and (2) a thorough physical exam. A life-threatening situation (such
as an off-label use of a drug that will cure an inoperable brain
tumor on a person with only a short time to live, treatment for a
congenital heart disease, AIDS, or cancer) will relax this require-
ment insofar as the patient will be able to try the new drug upon
FDA approval but need not undergo a physical exam.220 If it is
later proven that the condition was feigned in an effort to acquire
the drug, both the patient and the physician will be held account-
able.
B. Reasoning Behind the Proposal
The Congressional intent behind the establishment of the FDA
was to ensure safety.221 In accordance with such intent, the plain
meaning of the term "new drug" encompasses the very act of
dispensing off-label uses of drugs. It is true that a new drug
product requires a huge expense in terms of money, research and
time. However, it is only logical to take steps in an effort to ensure
as little risk as possible to the general public prior to the product's
220 A life-threatening situation is not amenable to the time constraints
imposed by the scheduling of a physical examination. Nor would it be reasonable
to have these victims succumb to further examination when they already have
been deemed gravely ill. Dispensing of off-label drugs to this very narrow
category may prove to be one's last resort to either prevent a further decline in
health or possibly improve the current condition.
221 O'REILLY, supra note 15, at 13-2.
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marketing, as opposed to having innocent people suffer and the
product later recalled amidst numerous litigation suits.
222
Describing [b]road developments in social-intellectual
history reminds us of the context within which the problem
of medical mishaps has taken center stage. Modem
industrial societies are committed, as never before, to
adopting technological innovations wherever these serve
the welfare of the individual members. In accepting this
general policy, they inevitably expose these individuals to
certain novel risks also. In earlier times, the consistent use
of "routine and accepted" procedures in all sectors of life
had given some people the assurance of knowing in
advance both the limited benefits and the limited risks they
could expect. Technological progress has raised the stakes
on both sides. The availability of new methods holds out
the reasonable prospect of major new benefits; but, at the
same time, it creates the likelihood that unforeseen hazards
will harm some fraction of those people who are on the
receiving end of those innovations.223
Medicine has historically been distinguished from business and
trade simply by appearing "above the market and pure commercial-
ism. ' 2 24 We revere our physicians' skill and trust that they will
222 See supra notes 151-171 (discussing litigation arising from various
adverse problems resulting from the use of fen-phen).
223 Mark Seigler & Mark Sheldon, Paying the Price of Medical Progress:
Causation, Responsibility, and Liability for Bad Outcomes after Innovative
Medical Care, in MEDICAL INNOVATION AND BAD OUTCOMES: LEGAL, SOCIAL,
AND ETHICAL RESPONSES 8 (Mark Siegler, et al. eds., 1987). The compelling
question is, "whether the progressive nature of American medicine and our
society should modify our philosophical and legal attitudes toward medical
maloccurrences and their compensation." Id.
224 PAUL STARR, THE SOCIAL TRANSFORMATION OF AMERICAN MEDICINE:
THE RiSE OF A SOVEREIGN PROFESSION AND THE MAKING OF A VAST
INDUSTRY 23 (1982).
Doctors' increasing authority had the twin effects of stimulating and
restricting the market. On the one hand, their growing cultural
authority helped draw the care of the sick out of the family and lay
community into the sphere of professional service. On the other, it also
brought political support for the imposition of limits, like restrictive
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make decisions that are in accordance with our best interests. With
this, we surrender our private judgment for that of another. Laws
prohibiting laymen from obtaining certain classes of drugs absent
a prescription only serves to increase our dependence on physicians.
"Printer's ink, when it spells out a doctor's promise to cure, is
one of the subtlest and most dangerous of poisons. 22 5 This in no
way implies that the sick are the best judge of their own needs.
Undoubtedly, scientific knowledge holds a privileged status in our
society. However, a problem arises when individuals who possess
such knowledge play on the infirmities of their patients.
Doctors are aware of their overweight patient's vulnerability.
However, whether a conscious decision or not, doctors are
capitalizing on such a characteristic by dispensing drugs for
unapproved purposes. Just as we should not put candy in front of
a diabetic or liquor in front of a recovering alcoholic, we should
not tempt the obese population with an unapproved drug combina-
tion that will inevitably lead people down the road of despair.
CONCLUSION
How often I have wished that I had a willowy body and
sculpted features like a movie star. I wished I were not just
normal, but thin. Despite idolizing thinner and thinner
women, Americans are growing fatter. A third of American
licensing laws, on the uncontrolled supply of medical services. By
augmenting demand and controlling supply, greater professional
authority helped physicians secure higher returns for their work.
Id. at 24.
225 STARR, supra note 224, at 131. Paul Starr addresses and analyzes what
it is that doctors sell as a commodity ... is it drugs, advice, time or availability?
It becomes rather suspect when a profession can so easily turn its authority into
economic gain. In particular:
Any physician who advertises a positive cure for any disease, who
issues nostrum testimonials, who sells his services to a secret remedy,
or who diagnoses and treats by mail patients he has never seen, is a
quack.. . . Shut your eyes to the medical columns of the newspapers,
and you will save yourself many forebodings and symptoms.
STARR, supra note 224, at 131.
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adults are now overweight, and many will swallow any
cure that comes along. But there's a price in swallowing
potentially fatal diet pills.226
As we come full circle we once again encounter the question:
who will regulate doctors when they are free to prescribe approved
drugs for any and all uses they desire? A patient's willingness to
try almost anything that a doctor prescribes mandates strict
regulation of what can be dispensed. Therefore, it is clear that off-
label uses of drugs create a new pharmacologic product that
requires FDA approval. The fen-phen disaster should educate the
federal health officials to step in sooner in an effort to "prevent [a]
tragedy."
227
226 Gail Boyer Hayes, Paying a High Price For the Promise of Thinness,
WASH. POST, Sept. 16, 1997, at Z 15. Nearly one-half of the people that develop
pulmonary hypertension die within three to five years, and the remaining
individuals are cursed with long-term heart problems. Id. Hayes is left
questioning, "[W]hy didn't her doctors or federal health officials step in sooner
to help prevent this tragedy?" Id. "The Food and Drug Administration, with
authority to regulate the drug industry, doesn't oversee these experiments, as one
might expect." See Richard Whitt, Clinical Trial & Errors Uncontrolled
Experiments Millions of Americans Submit Themselves as Human Guinea Pigs
in the Race To Try Out New Drugs, ATLANTA J.-THE ATLANTA CONST., Nov.
16, 1997, at DOI. "Squeezed between the vise-like jaws of public demand for
fast approval of the latest wonder drugs and congressional pressure to reduce red
tape, the FDA's review process is cursory at best and little more than a rubber
stamp at worst." Id.
22 Hayes, supra note 226, at Z 15. See Deadly Rx//Experience With Diet
Drug Shows Consumers and FDA Must Be Wary, HARRISBURG PATRIOT
(Harrisburg, Pa.), Nov. 19, 1997, at A10.
In short, fen-phen ranks as a major public health fiasco, one that has
quickly emerged as a full-employment project for trial lawyers. But the
broader questions are: How did this dangerous drug-combination
manage to elude the system of checks that every legally sold drug must
travel through before it can be sold on the market? Are there other
potentially harmful drug combinations that lie in wait for unsuspecting
consumers? ... For its part, the FDA needs to resist political pressures
to lower its standards to get drugs to the market faster, especially when
. . . plenty of grounds for being cautious and demanding more test
trials [exist].
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